# BECHEL v. SECRETARY OF HEALTH AND HUMAN SERVICES

> United States Court of Federal Claims · December 11, 2023

URL: https://www.frixlaw.com/law-library/cases/10736786

## Case

- **Court:** United States Court of Federal Claims
- **Decided:** December 11, 2023
- **Precedential status:** Unpublished
- **Opinion:** Opinion
- **Judges:** Brian H. Corcoran
- **Cited by:** 0 later opinions in the Frix Law Library

## Citator (automated)

- No negative treatment found by the automated citator. That is not the same as a confirmation that the case is good law; read the citing cases.
- Full citator and citing cases: https://www.frixlaw.com/law-library/cases/10736786

## How later opinions describe it (automated extraction)

- affirming special master’s determination that vaccine did not trigger afebrile seizure resulting in epilepsy

## Opinion text

CORRECTED

In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 16-887V

*************************
ALEX and TESS BECHEL, *
parents of G.J.B., a minor, *
* Chief Special Master Corcoran
Petitioners, *
* Dated: May 22, 2023
v. *
*
*
SECRETARY OF HEALTH AND *
HUMAN SERVICES, *
*
Respondent. *
*
*************************

Isaiah Kalinowski, Bosson Legal Group, Fairfax, VA, for Petitioners.

Colleen Clemons Hartley, U.S. Dep’t of Justice, Washington, DC, for Respondent.

ENTITLEMENT DECISION 1

On July 26, 2016, Alex and Tess Bechel filed a petition as parents of G.J.B., seeking
compensation under the National Vaccine Injury Compensation Program (the “Vaccine
Program”). 2 Petitioners allege that G.J.B. experienced encephalopathy, epilepsy, seizures,
delirium, confusion, altered mental state, and other injuries due to the administration of several
childhood vaccines on July 29, 2013. Petition (ECF No. 1) at 1–2.

The case was transferred to me in January 2021, and it had been set for an entitlement
hearing to be held in February 2022. After Petitioners’ initial counsel withdrew, however, it was

1
Under Vaccine Rule 18(b), each party has fourteen days within which to request redaction “of any information
furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or
confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly
unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the whole Decision will be available to the public
in its present form. Id.
2
The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660,
100 Stat. 3758, codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (2012) (“Vaccine Act” or “the Act”).
Individual section references hereafter will be to § 300aa of the Act (but will omit that statutory prefix).
vaccines: Kinrix (containing DTaP and IPV), 4 measles, mumps and rubella (“MMR”), and
varicella (“VAR”). Ex. 1 at 5; Ex. 3 at 47.

There is no contemporaneous record evidence of any reaction to these vaccines. However,
Ms. Bechel’s witness statement maintains that the next day (July 30 th), she “noticed his legs were
a little red and swollen around the site of injection,” and that he began “complaining of a headache
that evening and continued to complain over the next few days off and on.” Ex. 8 at ¶ 2. G.J.B.’s
grandmother, Kay Bechel, has also averred that on Wednesday, July 31, 2013 (two days post-
vaccination), G.J.B. developed “severe swelling in both of his thighs and a headache.” Ex. 10 at ¶
2.

Five days later, on Saturday, August 3, 2013, Ms. Bechel contacted Central Baptist
Hospital for an assessment of G.J.B.’s condition. Ex. 5 at 1. She reported that G.J.B. could not
remember some words, and did not know his name when asked. Id. The “onset/duration” was
noted as “today.” Id. The record of this communication also indicates that G.J.B. received his four-
year vaccinations on the previous Monday, and that he “had speech problems in the past with
stuttering.” Id. The record identifies no other physical issues at the time or newly-observed
symptoms, however, and reports G.J.B. to have been afebrile. Id. The nurse advised Ms. Bechel to
seek emergency treatment “immediately,” although the Petitioners did not do so. Id.

The day after (August 4 th), a nurse with Pediatric and Adolescent Associates followed-up
with Ms. Bechel. Ex. 3 at 48. Ms. Bechel confirmed that she had not yet taken G.J.B. to the
emergency room, and that he was still stuttering and getting frustrated. Id. The record memorializes
the note that “mom thinks this is all related to the 4 yr vaccines he got a few days ago.” Id. Ms.
Bechel also apparently reported at this time that G.J.B. did not have a history of this in the past,
and did not have any other injury or illness. Id. Ms. Bechel was advised to monitor his condition,
and bring him in the next day if concerns continued. Id.

On August 5, 2013, G.J.B.’s grandmother, Kay Bechel (who is apparently a registered
electroencephalographic technologist), completed an EEG of G.J.B. at her home. Ex. 20 at 1–23;
Ex. 10 at ¶ 4. While the notes are handwritten on the documentation filed, Kay Bechel has averred
that the study results appeared “abnormal” to her, and she therefore recommended that G.J.B. be
taken to his physician and a pediatric neurologist for a full work-up. Ex. 10 at ¶ 5. Ms. Bechel did
so the next day. Ex. 3 at 50–52.

At this pediatric visit, Ms. Bechel reported G.J.B.’s recent vaccinations, and that he had
complained of a headache after getting them. Id. Then, on August 3, 2013, he woke up “stuttering
really bad” with a “blank look on his face”—a completely novel behavior, followed by off-and-on
stuttering, and an instance where he forgot his name. Id. She admitted that G.J.B. had manifested

4
“DTaP” is the acronym for diphtheria-tetanus-acellular pertussis vaccine, and “IPV” is the acronym for polio vaccine.

3
some issues with speech before, and was enrolled in a Head Start Program, but noted that he did
not previously stutter. Id. The pediatrician observed G.J.B. stutter several times during the visit,
although when examined he was alert and oriented with no focal deficits. Id. The pediatrician
diagnosed G.J.B. with “stuttering” and referred him to Cincinnati Children’s Hospital for a
neurology consultation with Marissa Vawter, M.D. Id.

Post-Vaccination Evaluations and Epilepsy Diagnosis

On August 7, 2013, Petitioners took G.J.B. to St. Joseph Hospital for evaluation. See
generally Ex. 12. On admission, Ms. Bechel reported that G.J.B. had “started stuttering on
Saturday 7-29-13,” and that he was doing so “up to 30 times a day,” and often appeared “blank”
during the stuttering episodes. Id. at 49. G.J.B. underwent a one-day video EEG study at the
hospital. Id. at 34–35. The study yielded abnormal results and displayed 16 events, consisting of
stuttering of speech or repeating words, but with no other clinical change noted. Id. It specifically
revealed epileptiform discharges, most prominently in the left occipital electrode, and suggested
the possibility of multifocal/generalized epileptogenicity. Id.

G.J.B. was evaluated several days later by Dr. Vawter with the neurology service at
Cincinnati Children’s Hospital. Ex. 6 at 1–35. Ms. Bechel now provided a more detailed history
of G.J.B.’s health since the July vaccinations. Id. at 2. In particular, she represented that after leg
swelling G.J.B. began reporting headaches on July 30 th, and then on August 3rd began displaying
stuttering and an inability to remember his name, which was also evident at a birthday party he
attended, causing him to be upset and frustrated. Id. Such issues continued, and then by August
5th he had an episode of “spinning” while brushing his teeth. Id. Thereafter, his behaviors
progressed, the aforementioned home EEG was performed, and then by August 9, 2013, “when he
stuttered, his eyes seemed to get larger in size.” Id. A few days later, he appeared “hyperactive and
out of control.” Id. Ms. Bechel denied, however, any developmental regression or urinary
incontinence with any of the spells. Id.

In providing this history, Ms. Bechel also informed Dr. Vawter that G.J.B. had a history of
difficulties with enunciation shared in his family, plus a history of headaches, with Mr. Bechel
previously experiencing migraine-like headaches. Ex. 6 at 3. On physical examination, G.J.B. was
alert and his detailed neurological exam was normal. Id. at 4–5. Dr. Vawter opined that G.J.B. had
experienced at least two clinical seizures in the past ten days, singling out “the episodes where he
had abnormal verbal speech patterns and/or repetitions.” Id. at 5. In the context of his abnormal
EEG, Dr. Vawter documented that he met the criteria for epilepsy with “unknown etiology,” but
that medication could help stabilize and control his seizure activity. Id. To that end, Dr. Vawter
prescribed Keppra and ordered a brain MRI for further evaluation. Id. The brain MRI was
performed on August 19, 2013, Ex. 3 at 144–45. It revealed a hypoplasia left maxillary sinus, but
was otherwise unremarkable. Id.

4
On August 20, 2013, Ms. Bechel contacted the pediatrician’s office to inform them of
G.J.B.’s epilepsy diagnosis. Ex. 3 at 53. She also noted that G.J.B. had been complaining of his
right leg and right eye hurting, and that he often refused to walk. Id. However, when G.J.B. was
seen in the office the next day, he displayed no obvious musculoskeletal abnormalities on physical
examination. Id. at 54–55. At the end of August 2013, Kay Bechel submitted a VAERS report5 on
his behalf. Ex. 15 at 1; Ex. 10 ¶ 7. This report identified onset of G.J.B.’s symptoms (manifesting
as stuttering, repetition, and confusion) as August 3, 2013 (five days after the vaccinations),
although it also described his headaches as beginning sooner (July 31–August 2, 2013). Id. The
diagnoses reported included seizures, epilepsy, and an abnormal EEG. Id.

Further Treatment and Evidence of Other Comorbidities

About three months later (on November 12, 2013), G.J.B. was taken back to Dr. Vawter.
Ex. 6 at 74–111. At that time, Ms. Bechel reported that he had experienced no seizures or episodes
of stuttering since the initial visit in August, although he was having difficulty with his Keppra, so
alternative medications were discussed. Id. at 76, 79–80. G.J.B. saw Dr. Vawter again in February
2014, at which time Ms. Bechel reported that G.J.B. had experienced only one seizure since
changing anti-seizure medications. Id. at 123–185. Concerns were now also expressed about the
possibility of “developmental regression.” Id. at 124.

In March 2014, G.J.B. was evaluated at Cincinnati Children’s Rheumatology service for
joint pains for which he had obtained some treatment in the immediate months before. Ex. 3 at
135–38. On physical examination, G.J.B. displayed increased flexibility, particularly in his ankles
and knees, and laboratory testing was recommended to evaluate him for a possible underlying
autoimmune condition or thyroid condition. Id. That same month he also underwent an
ophthalmological evaluation which revealed hyperopia.6 Ex. 13 at 2–3. By May, treaters noted that
testing for autoimmune/rheumatologic conditions had produced normal results, and physical
therapy (“PT”) was recommended for G.J.B.’s joint pain. Ex. 3 at 139–40. Subsequent PT
evaluations revealed both functional weakness and gross motor delays. Ex. 7 at 4–7.
By early June 2014, G.J.B. had to be admitted to Cincinnati Children’s Hospital due to
increasing headaches, but was promptly discharged the next day. Ex. 6 at 1205–09. The headaches
5
The Vaccine Adverse Event Reporting System (“VAERS”) is a national warning system designed to detect safety
problems in U.S.-licensed vaccines. See About VAERS, VAERS, https://vaers.hhs.gov/about html (last visited May
19, 2023). It is managed by both the CDC and the FDA. VAERS monitors and analyzes reports of vaccine related
injuries and side effects from both healthcare professionals and individuals. See generally Carda v. Sec’y of Health &
Hum. Servs., No. 14-191V, 2017 WL 6887368, at *6 (Fed. Cl. Spec. Mstr. Nov. 16, 2017).
6
“Hyperopia” is defined as “an error of refraction in which rays of light entering the eye parallel to the optic axis are
brought to a focus behind the retina, as a result of the eyeball being too short from front to back.” Hyperopia, Dorland’s
Medical Dictionary Online, https://www.dorlandsonline.com/dorland/definition?id=23917&searchterm=hyperopia
(last visited May 22, 2023).

5
continued that month, however, and then in July G.J.B. was admitted to the University of
Cincinnati epilepsy monitoring unit for video monitoring. Id. at 1354–58. A brain MRI performed
at this time displayed a stable appearance of two tiny nonspecific areas of hyperintense signals,
which was thought to be gliosis. Id. at 1355; Ex. 3 at 146.

In September of that same year, G.J.B. underwent an occupational therapy evaluation for
fine motor delays. Ex. 7 at 1–3. Ms. Bechel informed treaters at this time that G.J.B. was no longer
taking anti-seizure medications, but was pursuing treatment from a new neurologist for “eye
flitting movements” and other abnormal behaviors. Id. By this time, G.J.B. was receiving physical
therapy once per week for leg and hip pain as well as muscle strengthening, and his occupational
therapy evaluation revealed fine motor deficits related to manual dexterity. Further epilepsy
monitoring was obtained in October 2014, but although Ms. Bechel reported G.J.B. to be often
waking at night unresponsive, and displaying other physical manifestations of seizure activity, a
video EEG revealed no clinical evidence of seizure. Ex. 4 at 1–77. G.J.B. returned to his
rheumatologist on December 15, 2014, and he was diagnosed with hypermobility and possibly
“Ehlers-Danlos syndrome.” 7 Ex. 3 at 141–42.

Treatment in 2015 and Beyond

On February 25, 2015, G.J.B. obtained an initial evaluation with Thomas Dye, M.D., at the
Neurology Clinic at Cincinnati Children’s Hospital (with Dr. Dye becoming his neurologic treater
thereafter). Ex. 6 at 645–76. G.J.B. was then reported to be experiencing worsening memory
problems over the last two months, although his neurological examination was normal, he
appeared alert and responsive, and his speech and articulation were also normal. Id. at 646, 650.
Dr. Dye assessed him with “generalized epilepsy,” noting as well that it did not appear his seizure
activity was as controlled as it could be. Id. at 650. Subsequent assessments of G.J.B. in the context
of his schooling that year confirmed that he was largely functional and meeting his goals. Ex. 17
at 75 (November 2015 assessment).

In 2016, Dr. Dye deemed G.J.B.’s seizure activity to be well controlled, although Ms.
Bechel noted that he had displayed some episodes in the wake of a fever, and anti-seizure
medications were adjusted to lessen the likelihood of side effects. Ex. 6 at 811–24. Rheumatologic
follow-ups also noted progress and improvement, despite some ongoing joint pain. Ex. 3 at 133–
34. By 2017, neuropsychological evaluations were evaluating whether G.J.B. should be medicated
for attention-deficit hyperactivity disorder and anxiety. Beyond that year he received educational
and treatment plans designed in light of this as well as his diagnosed epilepsy and Ehlers-Danlos

7
“Ehlers-Danlos syndrome” is defined as “a group of inherited disorders of connective tissue; formerly subdivided
into ten numbered types, they have been reclassified into six descriptive types. Prominent manifestations include
hyperextensible skin and joints, easy bruisability, and friability of tissues with bleeding and poor wound healing, with
additional symptoms specific for individual types.” Ehlers-Danlos syndrome, Dorland’s Medical Dictionary Online,
https://www.dorlandsonline.com/dorland/definition?id=110561 (last visited May 22, 2023).

6
syndrome. Ex. 38 at 4, and Exs. 83–85. Throughout the period as reflected by medical records
filed in this case, his seizures remained in good control. See, e.g., Ex. 86 at 45, 71, 137, 198, 207,
280.

II. Parties’ Expert Reports

A. Petitioners’ Experts

1. Marcel Kinsbourne, M.D.

Dr. Kinsbourne, a pediatric neurologist by training, prepared three written reports for this
matter. Report, dated Jan. 9, 2018, filed as Ex. 23 (ECF No. 25-1) (“First Kinsbourne Rep.”);
Report, dated Nov. 19, 2018, filed as Ex. 39 (ECF No. 32-1) (“Second Kinsbourne Rep.”); Report,
dated May 17, 2019, filed as Ex. 54 (ECF No. 38-1) (“Third Kinsbourne Rep.”).

Dr. Kinsbourne received his medical degree from Oxford University in England, along
with his Bachelor of Arts, and his Master of Arts. Curriculum Vitae, filed as Ex. 24 (ECF No. 25-
1) (“Kinsbourne CV”) at 1. He then received his M.D. from the State of North Carolina. Id.
Thereafter, Dr. Kinsbourne did several years of different post-doctoral training in neurology,
pediatrics, and chest diseases, and is a member of the American Board of Pediatrics and Royal
College of Physicians. Id. at 1–2. Dr. Kinsbourne held several academic positions—he was
previously a professor of psychology, professor of pediatrics, lecturer in neurology, adjunct
professor of linguistics and cognitive science, adjunct professor of occupational therapy, director
of the behavioral neurology department at the Eunice Kennedy Shriver Center, and other positions
related to neurologic and cognitive studies. Id. at 2–3. In addition, he also held positions on several
editorial boards, professional societies, and administrative assignments. Id. at 4–6. Dr. Kinsbourne
has conducted research into pediatric disorder, developmental delays and factors, cerebral
deficiencies, learning disabilities, therapies, and epilepsy. Id. at 6–39. Importantly, however, Dr.
Kinsbourne has not treated patients, pediatric or otherwise, for almost thirty years. 8

First Report

The initial part of Dr. Kinsbourne’s first report reviewed G.J.B.’s medical history. See
generally First Kinsbourne Rep. at 1–4. He emphasized the onset of G.J.B.’s stuttering on August
3, 2013, followed by related symptoms (“dysfluency,” word pronunciation difficulty, etc.) over
the coming days. Id. at 1–2. He also highlighted treater views that some of these early clinical
manifestations had likely been caused by seizures, and that his symptoms plus subsequent test
results met the criteria for epilepsy. Id. at 3. Dr. Kinsbourne concurred in the diagnosis of

8
See L.M. v. Sec’y of Health & Hum. Servs., No. 14-714V, 2019 WL 4072130 (Fed. Cl. Spec. Mstr. July 23, 2019)
(discussing Dr. Kinsbourne’s more recent practice experience).

7
epilepsy/seizure disorder, with some motor and processing delays attributable to it (or to the
medications needed to control seizures), although he deemed G.J.B.’s Ehlers-Danlos syndrome to
be unrelated. Id. at 3–4.

Dr. Kinsbourne also noted that G.J.B.’s speech-associated episodes were consistent with
seizure activity. Indeed, medicinal control of the seizures led to an end of such speech issues. First
Kinsbourne Rep. at 4. But the same medication regime could have secondarily sparked additional
symptoms, such as anxiety or issues processing information. Id. at 5. Otherwise, seizure disorders
(especially when experienced in infants) were reasonably understood to impact long-term
cognitive development and function. See, e.g., G. Holmes and Y. Ben-Ari, The Neurobiology and
Consequences of Epilepsy in the Developing Brain, 49 Ped. Research 3:320 (2001), filed as Ex.
64 (ECF No. 42-4), at 324 (review article noting that “prolonged or recurrent seizure activity” can
“irreversibly” impact an immature/pediatric brain, increasing greatly the risk of future seizure
susceptibility and associated injury).

Next, Dr. Kinsbourne proposed how the vaccines G.J.B. had received could be causal of
his seizure disorder. He highlighted the fact that nothing in G.J.B.’s pre-vaccination history
suggested a propensity for epilepsy (while diminishing the significance of “some problems with
[speech] articulation” that had unquestionably manifested earlier in G.J.B.’s life). First Kinsbourne
Rep. at 4. He focused on the MMR vaccine, noting that the underlying wild measles virus (included
in the vaccine, albeit in an attenuated form) was itself known to be “neuropathic,” and could thus
cause encephalopathy secondary to an infection, or even seizures themselves. Id. Government
publications had noted more directly that the vaccine had a causal association with “residual
seizure disorder.” K. Stratton et al., Adverse Events Associated with Childhood Vaccines Other
than Pertussis and Rubella, 271 JAMA 20:1602 (1994), filed as Ex. 68 (ECF No. 42-8) (“Stratton
I”).

Stratton I is somewhat less supportive of causation than alleged, however. It discussed
findings of committees established by the Institute of Medicine (the “IOM”) to evaluate potential
adverse effects of various vaccines. Stratton I specifically noted (in a summarizing chart) that the
evidence had been deemed “inadequate to accept or reject” any causal relationship between a
seizure disorder and vaccines containing tetanus/diphtheria-tetanus or measles. Stratton I at 1604.
Stratton I also differentiated between reliable evidence rejecting a vaccine association (which it
noted would in many cases have “insufficient statistical power to detect extremely rare causes of
an outcome”) and evidence suggesting a connection, stressing that “[t]he absence of data favoring
acceptance of a causal relation did not lead [the committees] to rejection of a causal relation
because of the possibility that adverse reactions might have occurred that have not been reported
or recognized.” Id. at 1603–04 (emphasis added). In other words, Stratton I was conservative in its
conclusions, and careful not to categorically rule out a vaccine-injury relationship merely because

8
there was little affirmative evidence of an association (although an equivocal finding of causality
either way did not mean that evidence favoring causality was abundant or even present).

A number of other publications, in Dr. Kinsbourne’s view, also confirmed the association
between vaccination and seizures (with the majority of the literature he cited focused on vaccines
containing a measles virus component). See generally Kinsbourne Rep. at 5; R. Alderslade et al.,
The National Childhood Encephalopathy Study (1981), filed as Ex. 62 (ECF No. 42-2)
(“Alderslade”) at 168 (UK study establishing that for children receiving measles vaccine from
January 1977 to the end of 1978, the relative risk of a seizure within two weeks of vaccination was
higher when compared to an unvaccinated control group); R. Weibel et al., Acute Encephalopathy
Followed by Permanent Brain Injury or Death Associated with Further Attenuated Measles
Vaccines: A Review of Claims Submitted to the National Vaccine Injury Compensation Program,
101 Pediatrics 3:383 (1998), filed as Ex. 70 (ECF No. 42-10) (“Weibel”) at 386 (based on review
of Vaccine Program claims through the date of publication, study identified 48 instances of acute
encephalopathy, followed by chronic encephalopathy/permanent or death, occurring within 2 to
15 days of receipt of measles or MMR vaccine, with 32 of the 48 first experiencing “generalized
or focal seizures”); P. Landrigan & J. Witte, Neurologic Disorders Following Live Measles-Virus
Vaccination, 223 JAMA 13:1459 (1973), filed as Ex. 29 (ECF No. 25-7) (“Landrigan & Witte”)
(considering incidence of different neurologic disorders after receipt of measles virus-containing
vaccines from 1963 to 1971, and observing instances of “prolonged or focal” seizures after
vaccination).

These specific items of literature, however, are only supportive of Petitioners’ claims in a
broad sense (to the extent they report observations of temporally-associated post-vaccination
seizure activity, but do not draw reliable conclusions about causality from them). Weibel, for
example, relied on cases filed in the Vaccine Program more than 30 years ago for its sample, and
does not disclose whether inclusion of instances in its sample was based on proof of the claim or
simply the claim’s allegations. Moreover, Weibel seems to have relied on the Table claim
framework for an encephalopathy after a measles virus-containing vaccine—a specific kind of
injury in which seizure can be a presenting symptom but which requires other proof of injury (and
indeed, the authors looked for cases resulting in “chronic encephalopathy or death”). 9 Weibel at
384. Although Weibel did perceive an association with the looked-for injury and the vaccine, it
acknowledged that “the incidence of acute encephalopathy caused by measles vaccine in this
cohort can reasonably be described as very low.” Id. at 387.

Alderslade relied on a very small total sub-sample (13 vaccinated individuals versus 10
controls), and the filed portion of this item of literature (a single page from a larger publication

9
In this case, Petitioner does not allege a Table encephalopathy, nor does the record establish the level of chronic
injury that would be sufficient to meet its requirements. 42 C.F.R. § 100.3(b)(2). Indeed, seizures are excluded by the
Table construction of the claim as a presenting symptom of encephalopathy, absent other/subsequent evidence of
injury. 42 C.F.R. § 100.3(b)(2)(i)(D).

9
containing a chart which provides the data relied upon by Dr. Kisnbourne) provides no information
about the nature or contours of the control group. Alderslade at 168. It also does not indicate if the
seizures observed were febrile—a critical issue here, given that G.J.B. was afebrile. Petitioner only
filed a one paragraph abstract from Landrigan & Witte—and that paragraph only states that the
article’s authors observed 84 total cases of post-vaccination neurologic disorders in a 30-day onset
(out of approximately 50 million vaccine doses in the relevant time period), with the majority (59)
involving “clinical features of encephalitis or encephalopathy”—injuries not alleged herein.
Landrigan & Witte at 1.

Some studies, Dr. Kinsbourne contended, actually linked onset of afebrile seizures to
vaccination (especially important here, since the record does not establish that G.J.B. experienced
a fever immediately before his initial, post-vaccination episodes). See, e.g., N. LeSaux et al.,
Decrease in Hospital Admissions for Febrile Seizures and Reports of Hypotonic-Hyporesponsive
Episodes Presenting to Hospital Emergency Departments Since Switching to Acellular Pertussis
Vaccine in Canada: A Report from IMPACT, 112 Pediatrics 5:e348 (2003), filed as Ex. 65 (ECF
No. 42-5) (“LeSaux”). Facially, LeSaux would not seem to be an item of literature supporting
Petitioner’s claim, since its ultimate conclusion was that febrile seizures after receipt of the then-
recently adopted acellular pertussis vaccine had decreased in a cohort of 218 Canadian children
who were vaccinated between 1995 and 2001, and who received the MMR or pertussis-containing
vaccine. LeSaux at e348. However, Dr. Kinsbourne observed, LeSaux recorded 16 of 94 instances
of post-MMR afebrile seizures—with seven occurring in children in the same age group as G.J.B.,
and seven experiencing “partial” seizures akin to what he had (although it is not evident from
LeSaux that these groups are actually congruent). Id. at e350, e351; First Kinsbourne Rep. at 5.

LeSaux, however, says nothing about the propensity of the MMR vaccine to cause afebrile
seizures, and it does not propose that the numbers Dr. Kinsbourne highlighted had scientific
meaning from a causation standpoint. At most, it comments that for the studied group the risk of
afebrile seizures after pertussis vaccine receipt declined, while the risk was the same for MMR.
LeSaux at e352. LeSaux allowed for the possibility that the afebrile seizure instances might have
involved undetected but transient or small temperature increases, or that children with a lower
seizure threshold were more likely to experience an afebrile seizure—but speculated that this may
have been attributable to the fact that “[a] higher proportion of children with afebrile seizures had
had previous afebrile seizures” compared to controls. Id. (emphasis added). Thus, LeSaux does
not robustly support a relationship between afebrile seizures and vaccination, even if its data reveal
some instances of post-vaccination afebrile seizures.

Dr. Kinsbourne concluded his first report with the opinion that G.J.B.’s onset was
consistent with a vaccine cause. First Kinsbourne Rep. at 4, 6. He deemed onset as occurring within
five days of vaccination, based on the record and as supplemented with witness statements. Id. at
4. In his estimation, onset occurring within as long as two weeks post-vaccination was “well-

10
recognized” to be validly associated, although he did not identify specific literature or studies
corroborating this contention. Id. And he emphasized the lack of alternative explanations for
G.J.B.’s seizure activity. Id. at 4, 6.

Second Report

This three-page report largely responded to the contentions of Respondent’s sole
neurologic expert, Dr. Shlomo Shinnar. Dr. Kinsbourne agreed that treaters had not accepted a
causal relationship between the vaccines and G.J.B.’s epilepsy, maintaining it was a
mischaracterization to suggest he had contended otherwise. Second Kinsbourne Rep. at 1. He
denied the significance of treaters deeming the epilepsy as “of unknown cause,” however, noting
that evidence presented and/or highlighted in this case could still support vaccine causation. Id. at
2. And he allowed that while individuals with Ehlers-Danlos syndrome might be susceptible to
epilepsy, the absence of evidence in this case that G.J.B. possessed any “comorbid structural
neurological abnormalities” undermined the possibility that this was explanatory herein (although
as noted below even Dr. Shinnar ultimately discounted Ehlers-Danlos syndrome as causal). Id. at
3.

Dr. Kinsbourne spent more time in his second report bulwarking his prior (albeit less-
discussed) contentions that even afebrile seizures could be vaccine-caused (although to some
extent he deferred to Petitioner’s immunologic expert, Dr. Vera Byers, for opinions on that
subject). Second Kinsbourne Rep. at 1–2. He referenced Weibel, for example, which found that
five vaccinated children included in the study who had experienced encephalopathy had also been
afebrile, versus 43 who had experienced a pre-encephalopathy fever. Weibel at 385. Again,
however, Dr. Kinsbourne has mined a facially-supportive point from data contained in an article
that actually says little (if anything) about the greater issue. Thus (and putting aside the fact that
he infers the five subjects in question experienced afebrile seizures, despite no affirmative
statement to that effect by Weibel’s authors), the sample total was quite small—48 vaccinated
patients—with the majority experiencing a fever. Id. at 385–86. Weibel otherwise has nothing to
say about post-vaccination risk of afebrile seizures, and focused on a different injury.

Another study, Dr. Kinsbourne maintained, also observed a small but significant number
of afebrile seizure events post-vaccination. N. Verbeek et al., Etiologies for Seizures Around the
Time of Vaccination, 134 Pediatrics 4:658 (2014), filed as Ex. 72 (ECF No. 42-12) (“Verbeek”).
Verbeek’s authors considered data from medical reports (from 1997 to the end of 2006) made to a
Dutch public health entity, beginning its analysis with a cohort of 1,269 children who appeared to
have experienced epileptic seizures within two years of life, then narrowing the sample to 990
children who had experienced a seizure within either 24 hours of receipt of DTaP vaccine or 5–20
days after the MMR. Verbeek at 659–60. Thus, Verbeek was deriving its conclusions based solely
on reports involving a temporal association with vaccination. From this group, moreover, only 26

11
children ultimately were found to have a vaccine-related temporal onset—and more data could
only be obtained through follow-up with the patients of 23 of these subjects, meaning the relevant
group ended up being quite small (especially in comparison to the sample totals Verbeek’s authors
began with). Id. at 660.

In addition, out of these 23 patients, Verbeek observed that three subjects with assumed
preexisting encephalopathy of some kind had experienced afebrile seizures, and that (as Dr.
Kinsbourne noted) it was more common for children who did not go on to develop epilepsy to
experience a higher temperature in the fever range than for those who did develop epilepsy. Second
Kinsbourne Rep. at 1; Verbeek at 661, 663. But Verbeek’s authors did not conclude that
vaccination was the likely cause of an epileptic disease/seizure disorder. Rather, Verbeek
speculated that “vaccination-related epilepsy” might unmask an existing genetic predisposition
(perhaps because subjects who experienced seizure after vaccination were simply likely to be more
sensitive to a smaller temperature change occasioned by vaccination). This said more about the
children in question than the effect of vaccination—as Verbeek’s authors allowed. Verbeek at 663
(“the large variability in electroclinical syndromes and corresponding cognitive outcomes in our
study support the hypothesis that predisposing factors in the child, and not the vaccination, cause
the observed neurologic deterioration”) (emphasis added), 665.

Dr. Kinsbourne further emphasized that even though an IOM Report cited by Dr. Shinnar
(from 2012—and hence generated nearly 20 years after the data discussed in Stratton I) did not
accept that sufficient evidence had been presented to associate the MMR vaccine with afebrile
seizures, the IOM had “elected to pitch the threshold for conceding causation at an extravagantly
high level”—in other words, requiring certainty (when in the Vaccine Program the evidentiary test
is lower). Second Kinsbourne Rep. at 2; Adverse Effects of Vaccines: Evidence and Causality 133–
37 (K. Stratton et al., eds., 2011), filed as Ex. A Tab 6 (ECF No. 28-7) (“Stratton II”).

Stratton II expressed a “high degree of confidence” in the findings of seven reliable
epidemiologic studies that the MMR vaccine was likely associated with febrile seizures, but (based
on only two large, controlled studies) placed “limited confidence” in the evidence suggesting an
MMR/afebrile seizures association. Stratton II at 133–34. At most, it deemed available
mechanistic evidence (ten items of literature in which afebrile seizures were reported after the
MMR vaccine’s administration, or receipt of its individual antigenic components (i.e., measles
vaccine alone) of the vaccine as causal of afebrile seizures to be “lacking,” since most studies
simply observed temporal associations, often too short to be meaningful. Id. at 134–37. Thus, while
Stratton II does not fully rebut Petitioner’s theory (at least in its consideration of what then-
available epidemiologic evidence showed), it does not reflect the demand for certainty for which
Dr. Kinsbourne criticized it.

12
Third Report

Dr. Kinsbourne’s final written report (succinct like the second) contained another round of
responses to Dr. Shinnar’s rebuttal contentions. First, he disputed the significance of the fact that
G.J.B.’s treaters had deemed his seizure disorder to be idiopathic in origin (as opposed to vaccine-
caused), asserting that this did not preclude vaccine causation. Third Kinsbourne Rep. at 1. Second,
he took issue with Dr. Shinnar’s characterization of Stratton II to be “authoritative,” noting that
the standards it set for accepting the possibility of vaccines being causal were so high that they
bordered on requiring certainty, and that other Program decisions had observed this to be so. Id. at
1–2. And Dr. Kinsbourne re-emphasized as relevant the lack of evidence of an alternative
explanation for G.J.B.’s illness, disagreeing with Dr. Shinnar’s contention that this could not stand
as indirect proof of causation; rather, Dr. Kinsbourne maintained, it was “normal procedure” in
Vaccine Program cases to highlight when there was no competing explanation for an injury other
than a vaccine. Id. at 4.

The majority of Dr. Kinsbourne’s third report addressed the more centrally-substantive
issue of whether vaccines are likely to trigger afebrile seizures. Third Kinsbourne Rep. at 2–3. Dr.
Kinsbourne noted at the outset that the association between febrile seizures and vaccination was
the product of “two independent effects”—the generation of fever due to vaccine-induced
upregulation of certain proinflammatory cytokines, versus seizure propagation/mediation
involving cytokines generally. Id. at 2. These two processes did not always occur simultaneously—
and it was even possible that a fever could follow a seizure. Id.; C. Waruiru and R. Appleton,
Febrile Seizures: An Update, 89 Arch. Dis. Child 751 (2004), filed as Ex. 84 (ECF No. 42-43)
(“Waruiru”).

Waruiru, however (a review article), is not supportive of Dr. Kinsbourne’s attempt to de-
link (or at least attenuate the relationship between) fever from seizures. Waruiru’s focus was the
characteristics of febrile seizures, and contains little discussion or evidence directly contrasting
them to afebrile seizures. Waruiru does allow that the timing of febrile seizures may vary (with
some occurring “early in the illness and may be the presenting feature”), and that the level of fever
necessary for a febrile seizure is undetermined (with no clear findings in science at the time of the
article’s publication as to whether the rate of temperature increase is more or less important than
the maximum temperature reached). Waruiru at 752. Thus, Waruiru does not find that afebrile
seizures are no more than “early” febrile seizures (i.e., occurring before the fever fully manifests)
triggered by the same pyrogenic or proinflammatory cytokines. At most, Waruiru comments that
(based on some evidence that certain anti-fever medication does not prevent febrile seizures) “it
may not be the fever itself that causes” the febrile seizure, but deems the “precise pathological or
clinical significance” of cytokine theories for seizure pathogenesis to be “as yet unclear.” Id.

13
Dr. Kinsbourne nevertheless maintained that an individual with a low seizure threshold
might experience “[t]he temperature rise that attends the triggering of a seizure” in a subclinical
or mild way, such that fever could be almost “overlooked.” Third Kinsbourne Rep. at 2. As an
example, Dr. Kinsbourne referenced Dravet syndrome,10 a genetically-caused seizure disorder
known to be triggered by vaccination, but where a “substantial minority” of individuals experience
no fever. Id.; see also I. Scheffer, Vaccination Triggers, Rather Than Causes, Seizures, 15
Epilepsy Currents 6:335 (2015), filed as Ex. 81 (ECF No. 42-21) (“Scheffer”) (noting that study
of children with Dravet syndrome revealed they often experienced the initial seizure in the
syndrome as afebrile but after vaccination, suggesting some role for the immune system in causing
it, but adding that this triggering factor was not fully understood, and that it may simply be the
product of the “first insult” for a child otherwise genetically predisposed to a seizure disorder). Dr.
Kinsbourne’s argument, however, depended on a finding that G.J.B. already possessed a low
seizure threshold, such that the trigger would be “the innate immune system’s reaction” to the
vaccine, rather than reaction to a vaccine-caused fever. Third Kinsbourne Rep. at 3.

Independent of these considerations, Dr. Kinsbourne maintained, there were other factors
supporting afebrile seizures as vaccine-associated. For example, he represented that it was
understood that a number of infections could likely provoke afebrile seizures. W. Lee and H. Ong,
Afebrile Seizures Associated with Minor Infections: Comparison with Febrile Seizures and
Unprovoked Seizures, 31 Pediatric Neurology 3: 157 (2004), filed as Ex. 74 (ECF No. 42-14)
(“Lee and Ong”). Lee and Ong is a retrospective cohort study that considered the medical histories
of Singaporean children who had been hospitalized after initial seizures, focusing on over a
thousand who had experienced a febrile seizure, 286 with “provoked” seizures—which the authors
defined to be seizures occurring in the context of an infection (evidenced by illness symptoms, like
cough) not typically affecting the brain, and not involving a fever at the time of seizure—and 125
with afebrile unprovoked seizures. Lee and Ong at 157–58. Lee and Ong ultimately concluded that
the groups with provoked and febrile seizures likely shared an “age-related seizure susceptibility,”
with the latter simply possessing a higher seizure threshold than the former—and (somewhat
contrary to Dr. Kinsbourne’s suggestion) that a viral infection itself was not necessarily the
triggering factor (since existence of virus was not found to be associated with more severe illness).
Id. at 163.

10
“Dravet syndrome” is defined as “an intractable developmental and epileptic encephalopathy that begins in infancy
and proceeds with accumulating morbidity that significantly impacts individuals throughout their lifetime. Dravet
syndrome is a rare disease, with an estimated incidence rate of 1:15,700, with the majority of patients carrying a
mutation in the sodium channel gene SCN1A.” See What is Dravet syndrome?, Dravet Syndrome Foundation,
https://dravetfoundation.org/what-is-dravet-syndrome/ (last visited May 19, 2023). Program cases have noted that
confirmation a child has the genetic basis for Dravet syndrome means even an unquestionably vaccine-caused febrile
seizure cannot be deemed the cause of the subsequent seizure disorder, and have thus denied entitlement. Oliver v.
Sec’y of Health & Hum. Servs., No. 10-394V, 2017 WL 747846 (Fed. Cl. Feb. 1, 2017), mot. for review den’d, 133
Fed. Cl. 341 (2017), aff’d, 900 F.3d 1357 (Fed. Cir. 2018).

14
Another study, Dr. Kinsbourne maintained, observed an association with influenza,
adenovirus, rotovirus, or RSV infections and afebrile seizures. B. Chung and V. Wong,
Relationship Between Five Common Viruses and Febrile Seizure in Children, 92 Arch. Dis. Child
589 (2007), filed as Ex. 78 (ECF No. 42-18) (“Chung and Wong”). But Chung and Wong
(conducting another retrospective study) focused on something different: whether specific viral
infections (which could trigger febrile seizures) were themselves most key to sparking seizure—
and also whether some were more likely causal than others. Chung and Wong at 589. They
concluded that although the relevant data set revealed influenza infections to be most commonly
associated with febrile seizures, “the type of viral infection was not found to be associated with
subsequent recurrence,” and that the more important risk factors for seizure disorders after an
initial seizure (even one unquestionably virus-provoked) were “[y]oung age at onset, complex
features and family history” of febrile seizure—with “individual susceptibility” the dominant
explanatory factor. Id. at 591. While the authors admitted secondarily to the existence of
“evidence” that certain viral infections, like gastrointestinal viruses, could be associated with
afebrile seizures, and that the subject warranted further consideration, they did not formally
propose the association for which Dr. Kinsbourne cited the paper.

Dr. Kinsbourne later admitted in his third report that the capacity of vaccination to trigger
afebrile seizures remained “rarely studied.” Third Kinsbourne Rep. at 3. But he maintained that at
least one study had (based on review of passive surveillance data) observed that any kind of seizure
was more likely on the first day after receipt of the DTaP vaccine. S. von Spiczak et al., A
Retrospective Population-Based Study on Seizures Related to Childhood Vaccination, 52 Epilepsia
8:1506 (2011), filed as Ex. 82 (ECF No. 42-22) (“Spiczak”). The article considered 328 cases of
“suspected vaccination-related seizures,” based on a German database of reported post-vaccination
adverse events, with follow-up inquiries directed at the patients and treaters involved to assess
post-initial seizure outcomes. Spiczak at 1506–07. The majority of the sample subjects had
experienced febrile seizures, however (with recipients of the MMR vaccine most likely to
experience a febrile seizure); less than 20 percent of the sample experienced a single afebrile
seizure. Id. at 1509. Spiczak was also not specific to DTaP or any other vaccine, 11 does not include
any findings identifying which vaccines are most likely to cause different types of seizures, and in
fact expressly disclaimed that it had shed light on relative risk or association between vaccines and
seizure outcomes. Id. at 1507–08, 1511 (because Spiczak’s authors relied on passive surveillance
reporting, “we are . . . unable to generate incidences or relative risks of certain epilepsy syndromes
in relationship to vaccination”).

11
At most, Spiczak references some supplemental tables that provide the kind of vaccine-specific evidence Dr.
Kinsbourne references with respect to DTaP. Spiczak at 1508. But none of those supplemental tables have been filed
with the version of Spiczak submitted in this case.

15
2. Vera Byers, M.D., PhD.

Dr. Byers (a medical doctor and immunologist with Immunology, Inc., a consulting
company) offered two written reports for Petitioners. Report, dated October 12, 2018, filed as Ex.
42 (ECF No. 32-4) (“First Byers Rep.”); Report, dated April 26, 2019, filed as Ex. 44 (ECF No.
37-1) (“Second Byers Rep.”).

Dr. Byers did not offer a CV in this case, but she has repeatedly testified in Program cases,
so her credentials are generally understood among the special masters. Dr. Byers received her
bachelor’s degree, master’s degree in microbiology, and Ph.D. in immunology from the University
of California, Los Angeles. See L.M. v. Sec’y of Health & Hum. Servs., No. 14-714V, 2019 WL
4072130, at *10 (Fed. Cl. Spec. Mstr. July 23, 2019). She completed two post-doctoral fellowships
before pursuing her medical degree—one in protein chemistry at Abbott Labs in Chicago, Illinois,
and another in clinical and tumor immunology at the University of California, San Francisco
(“UCSF”). Id. Thereafter, Dr. Byers received her medical degree and completed a three-year
residency at UCSF. Id. She has frequently served as an expert witness in lawsuits over the past
fifteen years, including Vaccine Program cases. Id. Throughout her career, Dr. Byers maintained
several positions as an allergist and immunologist performing research and clinical trials in a
variety of different areas. Id. Despite an extensive list of publications, Dr. Byers has not published
on the causes of seizures, nor on cytokine responses to vaccinations. Id.

First Report

Dr. Byers’s initial report was based on her own review of the medical record plus the initial
reports offered by Drs. Kinsbourne and Shinnar. First Byers Rep. at 1–2. She began by noting how
common febrile seizures are in children, and that science has linked fever with seizures due to the
production of pro-inflammatory cytokines. Id. at 2. However, she opined that the processes
involved in fever and seizures were “independent of each other,” such that cytokines might be
capable of causing seizures independent of fever. Id. One cytokine in particular, IL-1β, could
reduce seizure thresholds even if it could also cause fever, suggesting it might play such a dual
role. A. Mazarati, Cytokines: A Link Between Fever and Seizures, 5 Epilepsy Currents 5:169
(2005), filed as Ex. 73 (ECF No. 42-13) (“Mazarati”) (noting the scientific possibility that because
afebrile seizures appeared to encourage production of IL-1β, the cytokine might also itself
contribute to the exacerbation of seizures). Mazarati, however, is only a commentary on an item
of literature Petitioner did not file, and it notes that the role this cytokine plays in infection-
associated seizures has not been fully assessed. 12 Mazarati does not otherwise establish that the

12
Mazarati includes a diagram that Dr. Byers reproduced in her first report. Compare Mazarati at 170 with First Byers
Rep. at 2. Dr. Byers erroneously referred to Mazarati as “Dube” (the article it discusses)—an article Petitioners did
not file—although she cited to it the source of this diagram. Petitioners’ exhibit filings repeated this error—thereby
causing confusion on Dr. MacGinnitie’s part, when he accessed the underlying article independently but was unable
to find the diagram therein. See Report, date January 29, 2019, filed as Ex. C (ECF No. 33-1), at 5–6.

16
IL-1β cytokine equally responds to pyrogenic signals from viruses (resulting in fever) in the same
way as it might independently contribute to a seizure, and in the absence of an external infection.

Dr. Byers maintained that afebrile seizures were distinguishable from febrile, both in terms
of triggers and features. First Byers Rep. at 2–3. Some studies, for example, observed that certain
kinds of infections had a “better prognosis” after an afebrile seizure than other kinds of infection-
associated afebrile seizures (or seizures unprovoked by any infection). Id. at 3; T. Zhang et al., Are
Afebrile Seizures Associated with Minor Infections a Single Seizure Category? A Hospital-Based
Prospective Cohort Study on Outcomes of First Afebrile Seizure in Early Childhood, 55 Epilepsia
7:1001 (2014), filed as Ex. 53 (ECF No. 37-10) (“Zhang”). Zhang, however, is narrowly focused
on a general association observed from the data its authors obtained, does not comment on the
differing roles cytokines might play in febrile vs. afebrile seizure contexts, and also notes that in
cases where the afebrile but infection-associated seizure was accompanied by acute symptoms, the
afebrile seizure was “in all probability an entity in the same category with febrile seizures of acute
symptomatic seizures”—meaning the ultimate outcome was essentially the same (in comparison
to fully-unprovoked seizures). Zhang at 53.

The cytokine profiles for individuals suffering from the two different kinds of seizures
were also distinguishable, Dr. Byers argued. First Byers Rep. at 3. In fact, Dr. Byers suggested
that patients with febrile seizures likely possessed elevated levels of types of cytokines that were
“potent anti-epileptogenic agents” (thus perhaps explaining why febrile seizures did not invariably
lead to seizure disorders), although Dr. Byers did not so directly opine, and the “recent study” she
specifically referenced for this point was never filed. Id. Indeed, Dr. Byers referenced two other
items of literature that she reported showed different kinds of cytokine levels in febrile seizure
patients that she represented were relevant to her contentions, but both were unfiled. Id.

Given the foregoing, Dr. Byers opined that the core difference between afebrile and febrile
seizures was merely cytokine profiles—and so (presumably) since IL-1β could always be
upregulated by vaccination, the absence of fever did not mean the vaccine was less likely causal.
First Beyers Rep. at 3. Dr. Byers did not, however, explain how vaccination would cause the
production of this cytokine at levels sufficient to precipitate seizure, and then lead to a seizure-
oriented illness, without also causing fever.

Second Report

Dr. Byers’s second report was as brief as the first, although she expanded her focus to
include responses to the opinions offered by Respondent’s immunologic expert, Dr. Andrew
MacGinnitie. She reemphasized her contention that “cytokines cause fevers and the seizures
independently,” citing again an item of literature never filed in this case in support. Second Byers
Rep. at 1. In effect, the cytokines produced in reaction to vaccination would have the same effect

17
as a mild infection—and thus a vaccine-induced afebrile seizure was comparable to a “provoked”
seizure caused by an infection (relying on the seizure classifications proposed in Lee & Ong). Id.
at 2. In addition, the fact that G.J.B. likely had experienced the presence of pro-inflammatory
cytokines sufficient to provoke seizures was evidenced by the leg swelling and headaches that he
had undergone after vaccination, as reported by his family members. Id. Thus, to the extent
Respondent’s experts questioned whether febrile and afebrile seizures could have comparable
etiologies, they displayed their ignorance of “the current neuro/science” on the topic. Id. at 1, 3
(deeming Respondent’s expert’s analyses “out of date”).

In further support of her opinion on this subject, Dr. Byers identified a study observing that
a different cytokine from what she had previously identified, tumor necrosis factor alpha (“TNF-
alpha”), was present in the serum of patients with afebrile seizures, but at levels compatible to
those patients who had experienced fever but no seizures.13 J. Ha et al., Interleukin-4 and Tumor
Necrosis Factor-Alpha Levels in Children with Febrile Seizures, 58 Seizure 156 (2018), filed as
Ex. 47 (ECF No. 37-4) (“Ha”).

Ha sought to delve into the pathophysiology of febrile seizures (and in particular the role
cytokines play in causing them). To do so, its authors compared blood serum measurements
obtained from 50 subjects who had experienced febrile seizures against a control group of 39—
but also considered 13 afebrile subjects independently, “to exclude the effects of fever on cytokine
levels.” Ha at 157. Although Dr. Byers’s characterization of the specific TNF-alpha cytokine level
findings in Ha is accurate, the detected levels of that cytokine were highest in the febrile seizure
group with a history of past febrile seizures, and slightly lower than the primary febrile seizure
group subjects—suggesting the cytokine’s levels might be attributable to seizure activity itself. Id.
at 158 – 160. The levels of a different cytokine were lowest of all in the afebrile group, and both
measured cytokines were lower in the afebrile group compared to febrile subjects. Id at 159. Thus,
all things being equal, the afebrile groups possessed lower levels of any putatively seizure-causing
cytokines (making it difficult to conclude from such findings that the mere presence of these
cytokines induced seizure). More importantly, although Ha’s authors deemed “convincing” the
argument that (assuming “[c]ells from children who are prone to seizures may produce more pro-
inflammatory cytokines” that in turn induce seizures) cytokine levels might relate to seizure
incidence, they only so opined with respect to febrile seizures, offering no opinion on the role these
cytokines would play in the absence of fever. Id. at 159.

13
By contrast, Dr. Byers noted that another item of literature revealed low levels of TNF-alpha cytokines in individuals
with afebrile seizures—although in her estimation, the fact that individuals who had experienced afebrile status
epilepticus had high levels of these cytokines, and others, supported her broader contention that the cytokines could
cause seizure regardless of fever. Second Byers Rep. at 3. However, the item she referenced for this point was (like
several others) never filed.

18
Dr. Byers referenced several additional studies specific to vaccines. One, she purported,
considered a small subset of children who had experienced afebrile seizures within 30 days of
receipt of the DTP (a whole-cell pertussis formulation not at issue in this case) and MMR vaccine.
Second Byers Rep. at 2; W. Barlow et al., Risk of Seizures Following DTP and MMR Vaccines,
15 Pediatric Neurology Briefs 9:65 (J. Millichap, ed.) (2001), filed as Ex. 50 (ECF No. 37-7)
(“Millichap”). The item filed, however, is merely the underlying article’s abstract. And the cited
article reported far fewer afebrile seizures in comparison to febrile (74 febrile after vaccination
versus 13 afebrile, with only three after the MMR vaccine). Millichap at 65. Dr. Byers also
referenced Lee and Ong as establishing instances in which afebrile “provoked” seizures
occurred—ostensibly because this showed that a mild infection (which Dr. Byers seemed to equate
to the effect of vaccination) could cause seizure despite the absence of fever. Second Byers Rep.
at 2; Lee and Ong at 157, 163.

Case reports were deemed by Dr. Byers supportive of the vaccine-seizure association she
proposed. In one, a child experienced nonfebrile seizures within one to two weeks after receipt of
vaccines comparable to the MMR or varicella vaccines. I. Eckerle et al., Nonfebrile Seizures After
Mumps, Measles, Rubella, and Varicella-Zoster Virus Combination Vaccination with Detection of
Measles Virus RNA in Serum, Throat, and Urine, 20 Clin. And Vaccine Immun. 7:1094 (2013),
filed as Ex. 46 (ECF No. 37-3) (“Eckerle”). The patient discussed in Eckerle was eleven, however,
and even a year after the vaccine-associated seizure had not experienced any additional seizures
or signs of epilepsy. Eckerle at 1094–95. Eckerle’s authors referenced two additional incidents in
Germany of nonfebrile seizures after receipt of the MMR vaccine, although they were identified
from a search of a German vaccination adverse events database comparable to VAERS, and
Eckerle affirmatively noted that the overall case report could not stand as evidence of a causal link
between vaccination and afebrile seizures. Id. at 1095–96.

At bottom, Dr. Byers allowed that febrile-associated seizures were more common after
vaccination, but she attributed this to the fact that fever “is one of the most common adverse
events” of vaccination. Second Byers Rep. at 3. What was really determinative of seizure
susceptibility was the child’s age—and thus the absence of a febrile seizure simply revealed a high
susceptibility to seizures per se, which could be triggered simply by sufficient provocation (here,
the cytokine increase she deemed attributable to vaccines). Id. The latter possibility, she
maintained, was established by several independent items of literature. See, e.g., G. Li et al.,
Cytokines and Epilepsy, 20 Seizure 249 (2011), filed as Ex. 75 (ECF No. 42-15) (“Li”). Li sought
to cast some light on the “complex relationship between epilepsy and the immune system” by
providing an overview on the current knowledge” about the association, reviewing a large number
of studies with respect to three different cytokines: IL-1β, IL-6, and TNF-alpha. Li at 249. Li’s
authors observed that IL-1β is involved in epilepsy’s pathogenesis generally, and in mediating
seizures specifically—but not that this cytokine is likely causal of all initial seizures (febrile or

19
afebrile), or that vaccines upregulate the cytokines in levels sufficient to be seizure-inducing.14 Id.
at 250 – 51.

B. Respondent’s Experts

1. Shlomo Shinnar, M.D.

Dr. Shinnar is a pediatric neurologist with demonstrated specific expertise in treatment of
epilepsy, and he prepared three written reports for Respondent. Report, dated April 22, 2018, filed
as Ex. A (ECF No. 28-1) (“First Shinnar Rep.”); Report, dated March 6, 2019, filed as Ex. E (ECF
No. 36-1) (“Second Shinnar Rep.”); Report, dated Sept. 9, 2019, filed as Ex. G (ECF No. 47-1)
(“Third Shinnar Rep.”).

Dr. Shinnar received his undergraduate degree in physics from Columbia College in New
York, NY in 1971, and his Ph.D. and medical degree from Albert Einstein College of Medicine in
Bronx, NY in 1977 and 1978. Curriculum Vitae, filed as Ex. B on Apr. 27, 2018 (ECF No. 28-13)
(“Shinnar CV”) at 1. He completed his training in 1983 and has practiced neurology since. Shinnar
CV at 1. He became board certified by the American Board of Psychiatry and Neurology in
Neurology with special competence in Child Neurology (1984) with an added Qualification in
Epilepsy (2013) Shinnar CV at 2; Shinnar First Rep. at 1. Dr. Shinnar is also board certified in
Pediatrics (1984). Id. Currently, he is Professor of Neurology, Pediatrics, and Epidemiology and
Population Health at Albert Einstein College of Medicine. CV at 2; Shinnar First Rep. at 1. Dr.
Shinnar is also the Hyman Climenko Professor of Neuroscience Research and the Director of the
Comprehensive Epilepsy Management Center at Montefiore Medical Center and the Albert
Einstein College of Medicine. Id. He has treated and supervised thousands of children with seizure
disorders, and has conducted research primarily focused on childhood seizures. Id. In addition, Dr.
Shinnar has published numerous papers and reviewed articles and chapters, a majority of which
relate to seizure disorders. Id.

First Report

Like Dr. Kinsbourne, Dr. Shinnar provided his own overview of G.J.B.’s medical history.
See generally First Shinnar Rep. at 3–5. He noted (and perhaps gave a bit more emphasis to) the
pre-vaccination evidence of G.J.B.’s “speech deficit,” along with other more circumstantial
evidence about family neurologic issues. Id. at 3–4. Dr. Shinnar also acknowledged record

14
At most, Li mentioned that seizures induced by the now-discontinued whole cell pertussis vaccine could be reduced
if IL-1β were inhibited, confirming that this cytokine is significant in contributing to febrile seizures (especially when
another antigen is likely the primary instigator). Li at 250. But the fact that this cytokine, or others, mediates seizure
activity cannot be equated with being causal by itself.

20
evidence of a five-day, post-vaccination incident of stuttering, although he maintained that
subsequent EEG testing suggested that this episode was nonepileptic in character. Id. at 4.

Dr. Shinnar agreed with G.J.B.’s epilepsy diagnosis. First Shinnar Rep. at 5. He also
proposed, however, that G.J.B. likely possessed certain risk factors for epilepsy, such as his
preexisting speech issues and his Ehlers-Danlos syndrome, 15 which literature that he filed
associates with epilepsy. Id; A. Verrotti et al., Ehlers-Danlos Syndrome: A Cause of Epilepsy and
Periventricular Heterotopia, 23 Seizure 819 (2014), filed as Ex. A Tab 1 (ECF No. 28-2). But Dr.
Shinnar ultimately felt a diagnosis with an “unknown cause” explanation (meaning idiopathic) best
captured G.J.B.’s presentation overall—especially since his secondary speech issues later
resolved, while brain imaging had produced normal results. First Shinnar Rep. at 5. In Dr.
Shinnar’s experience, most cases of epilepsy lacked an identifying cause (thus reducing for him
the persuasive value of the fact that in this particular case, only vaccination had been specifically
identified as potentially explanatory). Id.; Epilepsy Across the Spectrum: Promoting Health &
Understanding (M. England et al., eds.) (2012), filed as Ex. A Tab 2 (ECF No, 28-3)
(“England”). 16

Dr. Shinnar attempted to rebut Dr. Kinsbourne’s contentions that epilepsy could be caused
by the MMR vaccine. First, he observed that any such association was specific to the context of
febrile seizures. First Shinnar Rep. at 5 (citing Stratton II). But G.J.B. had not experienced a febrile
seizure. Stratton II actually was noncommittal as to whether a relationship existed between afebrile
seizures and the vaccine, and other items Dr. Kinsbourne offered were either now greatly outdated
or lacked reliable methodologic controls. See, e.g., First Shinnar Rep. at 5 (referencing Weibel as
“without controls or a denominator”). And although Dr. Kinsbourne’s first report focused almost
wholly on the MMR vaccine, Dr. Shinnar also referenced literature disputing a reliable association
between the DTaP vaccine (which G.J.B. had also received) and seizures. First Shinnar Rep. at 5
(citing W. Huang et al., Lack of Association Between Acellular Pertussis Vaccine and Seizures in
Early Childhood, 126 Pediatrics 263 (2010), filed as Ex. A Tab 7 (ECF No. 28-8)) (“Huang”).

Huang’s authors conducted a retrospective observational study relying on Vaccine Safety
Datalink data of over 430,000 children (aged six weeks to 23 months) who received the DTaP
vaccine between 1997 and 2006, looking for instances in which individuals within the cohort also
had been deemed (according to uniform diagnostic classifications applicable to all relevant patients
in the sample) to have experienced a seizure. Huang at 264. No increased risk of seizure was

15
Later in this first report, however, Dr. Shinnar more forthrightly opined that Ehlers-Danlos syndrome did not in this
case likely explain G.J.B.’s epilepsy, since Petitioner’s imaging results had not revealed issues with his brain. First
Shinnar Rep. at 6.
16
Respondent opted to file the entirety of England’s text—569 pages—rather than simply those portions relevant to
Dr. Shinnar’s argument. That sort of conduct is wasteful, and also prevents me from identifying what in England
would specifically support this aspect of Dr. Shinnar’s report.

21
observed within zero to three days of vaccination—especially notable in light of prior findings of
a higher risk for the acellular form of pertussis contained in DPT. Id. at 268. Huang did not
distinguish between risks for febrile versus afebrile seizures (or even identify the distinction in
parsing the data), but did note that although both the DPT vaccine and MMR had been associated
in the past with febrile seizures, the same association had not been observed for afebrile seizures.
Id. at 263 – 64, 267.

Dr. Shinnar took less issue with Dr. Kinsbourne’s contentions about the secondary
relationship between epilepsy and subsequent cognitive difficulties. First Shinnar Rep. at 5.
However, he proposed that these kinds of additional symptoms/clinical presentations might well
be better understood to be baseline conditions often observed in advance of a seizure disorder
diagnosis, and thus could themselves be seen as causal of the epilepsy itself. Id; P. Fastenau et al.,
Neuropsychological Status at Seizure Onset in Children, 73 Neurology 526 (2009), filed as Ex. A
Tab 8 (ECF No. 28-9) (“Fastenau”). Fastenau involved a prospective study comparing a cohort of
282 children who had experienced a seizure versus 147 healthy siblings. Fastenau at 5262–67. The
possession of additional risk factors (including whether the seizure disorder’s etiology was
associated with a presumed prior condition) greatly increased the likelihood that a child
experiencing seizures would go on to develop more significant neuropsychological impairment.
Id. at 528–29, 532. Dr. Shinnar also denied that the temporal association in this case between
Petitioner’s first manifestation of symptoms and earlier vaccination was meaningful—in particular
because the seizures were afebrile (given that it was known only that vaccines can trigger febrile
seizures). First Shinnar Rep. at 5.

Second Report

Dr. Shinnar’s next report responded to Dr. Byers’s first report, as well as criticisms leveled
against him by Dr. Kinsbourne. Second Shinnar Rep. at 2. He reiterated the medical history
timeline before providing additional opinions. Id. at 2–4. In particular, Dr. Shinnar emphasized the
fact that G.J.B.’s treaters had not affirmatively embraced vaccination as causal, but instead only
deemed his epilepsy/seizure disorder “of unknown cause”—rejecting Dr. Kinsbourne’s contention
that this left room for vaccination as causal (since presumably the treaters would have said so if
they believed vaccination had played a role). Id. at 4; Ex. 6 at 79. He also noted that the definition
he employed for “unknown cause” was derived from the International League Against Epilepsy,
and thus did not reflect a permissive or open-ended framework that left room for vaccination as
causal. Guidelines for Epidemiologic Studies on Epilepsy, 34 Epilepsia 4:592 (Commission on
Epidemiology and Prognosis, Int’l League Against Epilepsy, eds.) (1993), filed as Ex. A Tab E
(ECF No. 36-1), at 593–94.

Dr. Shinnar stressed that the record showed G.J.B. possessed some deficiencies pre-
vaccination, and which likely had some association to his subsequent epilepsy. Studies had

22
recognized that such symptoms (along with the reported family history of problems) were often
present in individuals when seizures first manifest—and thus underscored why in this case G.J.B.’s
seizure disorder was best deemed the product of an unknown etiology. Second Shinnar Rep. at 4,
referencing Fastenau; see also D. Masur et al., Pretreatment Cognitive Deficits and Treatment
Effects on Attention in Childhood Absence Epilepsy, 81 Neurology 1572 (2013), filed as Ex. A
Tab 9 (ECF No. 28-10 (“Masur”). Masur conducted a double-blind, randomized clinical study of
446 children recently diagnosed with a previously-untreated form of epilepsy often deemed
benign, finding that secondary symptoms are not only associated with it but (a) can be present
when seizures begin, and (b) can persist even after seizures are medically controlled. Masur at
1573, 1577–79.

Dr. Shinnar then reacted to Dr. Kinsbourne’s comments. See generally Second Shinnar
Rep. at 4–5. He maintained that the evidence G.J.B.’s seizures had been afebrile undermined a
vaccine association, given existing medical/scientific understanding. The IOM’s conclusions
contained in Stratton II, he contended, had reliability and probative value at least because they
were based on the review of then-existing literature on the lack of association between the MMR
vaccine and afebrile seizures. Id. at 4; Stratton II at 134. By contrast, Dr. Shinnar deemed Verbeek
of limited persuasive value—for Verbeek had identified only three out of 990 children who
experienced post-MMR vaccine afebrile seizures, with two having possessed a family history of
afebrile seizure. Verbeek at 661. Verbeek also involved children far younger than G.J.B., further
eliminating the weight its otherwise-limited findings should be given. Second Shinnar Rep. at 4.

Dr. Shinnar concluded the report with his reactions to Dr. Byers’s report. Second Shinnar
Rep. at 5–6. He deemed her opinion “confusing at best,” observing the circular nature of her
statement that since febrile seizures were common, physicians likely assumed all seizures were
febrile—especially since (as was definitely established by the medical record herein) G.J.B.’s
seizures unquestionably were not febrile. Id. at 5. And he disagreed with her specific point that
any kind of seizure (febrile or afebrile) would have the same general cytokine-associated
mechanism, noting that the item she cited for this proposition 17 did not actually support the
contention, but instead (as evidenced by its title) was specific only to the association between IL-
1β and febrile seizures. Id.

As support for his argument that febrile and afebrile seizures did not likely share a common
immunologic mechanism, Dr. Shinnar offered a textbook chapter he had authored. S. Shinnar,
Febrile Seizures, in Swaiman’s Pediatric Neurology, Vol. 1 (5 th ed. 2012), at 790–97, filed as Ex.
3 Tab 1 (ECF No. 36-2) (“Shinnar”). Shinnar specifically states that most febrile seizures occur
after manifestation of fever, are thought more associated with peak temperature than rate of rise of

17
Dr. Shinnar’s comments on this subject were directed at “Dube,” an article Petitioner did not actually file, as
previously discussed. But it appears Dr. Shinnar was familiar with its content, and therefore was able to comment
upon it. Second Shinnar Rep. at 5 (terming it “an elegant paper which I am very familiar with”). Dr. MacGinnitie,
however, did offer this article in connection with his report, and I address it below.

23
temperature, and are more associated with some kinds of infectious processes than others (although
their ultimate pathophysiology is unknown). Shinnar at 791–92. In addition, Shinnar observes that
although febrile seizures do not always lead to development of epilepsy, certain risk factors
(neurodevelopmental abnormalities, family history, or the complexity and temporal proximity of
fever to seizure) are so associated if combined with febrile seizure occurrence. Id. at 794. The only
relevant comment herein about afebrile seizures, however, is the fact that children with neurologic
abnormalities and who have experienced febrile seizures are more likely to experience afebrile
seizures later. Id. at 790.

Third Report

The final written report authored by Dr. Shinnar reacted to the additional supplemental
reports from Drs. Kinsbourne and Byers. Regarding Dr. Kinsbourne, Dr. Shinnar again repeated
his contention that the record best supported an idiopathic/unexplained cause for G.J.B.’s epilepsy,
noting that in his experience, epileptologists assumed “unknown” to mean of unidentified genetic
origin. Third Shinnar Rep. at 6. He further noted that Scheffer had in fact discussed a body
temperature reflective of fever in discussion of seizure etiology, adding that IL-1β unquestionably
was the “chief human cytokine involved in triggering fever,” and that even when fever occurs after
seizure manifestation, it still occurs. Id.; Scheffer at 336 (observing that “[t]he immune basis is
not understood” for why a vaccine might arguably trigger seizure in a susceptible child).
Otherwise, literature (like Stratton II) only reliably observed an association between vaccines like
the MMR and febrile seizures—and again, G.J.B. had not experienced a post-vaccination febrile
seizure. Third Shinnar Rep. at 6.

Dr. Shinnar also criticized Dr. Byers’s supplemental arguments. Third Shinnar Rep. at 6–
7. He again maintained that literature she had referenced did not establish that seizures, febrile or
not, all involve IL-1β. Id. at 6. And he sought to refute Dr. Byers’s contention that he was not up
to date on the latest science on the cause of afebrile seizures, noting that his regular work includes
large government grants to study children who suffer from prolonged febrile seizures, and that he
had published many other articles specific to that issue as well as the role cytokines play in
seizures. Third Shinnar Rep. at 6–7.

In addition, Dr. Shinnar reacted to some other items of literature referenced by Dr. Byers.
Lee and Ong, for example, not only was a retrospective historical analysis of outcomes (instead of
a case-controlled study) but dealt only with “new onset seizures,” and said nothing about vaccine
association. Third Shinnar Rep. at 7; Lee & Ong at 157, 159. He deemed Lee & Ong to adopt a
“controversial” classification for seizure etiologies, moreover, and noted that Dr. Byers’s embrace
of this classification system underscored the lack of generally-sufficient on-point literature filed
in this matter specific to the alleged vaccine-afebrile seizure connection. Third Shinnar Rep. at 7.
Ha, Dr. Shinnar maintained, only observed the existence of higher TNF-alpha cytokine levels in

24
children with seizure disorders, and did not establish causality; indeed, Dr. Shinnar noted, it was
equally likely the seizures themselves were the cause of the expression of these cytokines rather
than vice-versa. Ha at 159; Third Shinnar Rep. at 7.

2. Andrew MacGinnitie, M.D., PhD.

Dr. MacGinnitie served as Respondent’s immunologic expert, and prepared two written
reports opining against vaccine causation of G.J.B.’s afebrile seizures. Report, dated January 29,
2019, filed as Ex. C (ECF No. 33-1) (“First MacGinnitie Rep.”); Report, dated July 29, 2019, filed
as Ex. F (ECF No. 44-1) (“Second MacGinnitie Rep.”).

Dr. MacGinnitie is an attending physician and the Clinical Director for the Division of
Immunology at Boston Children's Hospital in Boston, Massachusetts. Curriculum Vitae, filed as
Ex. D on Feb. 12, 2019 (ECF No. 34-6) (“MacGinnitie CV”), at 1–2. He is also an Associate
Professor of Pediatrics at Harvard Medical School. MacGinnitie CV at 1. Dr. MacGinnitie received
his undergraduate degree from Yale University, followed by both a medical degree and Ph.D. from
the University of Chicago. Id. Thereafter, he completed his residency, followed by a fellowship in
allergy and immunology at Boston Children’s. Id. He is board certified in pediatrics and allergy
and immunology, and has been in practice as an allergist/immunologist since 2004. Id. at 9.
Further, he has not only seen patients with various immunologic diseases, including reactions to
vaccines, but has published several articles in the area. Id. at 11–14.

First Report

Dr. MacGinnitie’s first report reacted to the initial opinions offered by Drs. Kinsbourne
and Byers. He admitted that he had “struggled to follow a logical theory of how vaccination
triggered seizures” as set forth in their reports, but had nevertheless attempted to comprehend their
theories. First MacGinnitie Rep. at 3. He interpreted Dr. Kinsbourne’s opinion to focus on the
MMR vaccine’s general capacity to cause seizure (as well as the secondary issues attributable to
the overall epilepsy/seizure disorder and/or treatment of it), while he read Dr. Byers’s report to be
maintaining that any of the vaccines G.J.B. had received could cause fever but also could lower
the seizure threshold, and thus cause seizures even in the absence of fever. Id. In either case, Dr.
MacGinnitie opined, the theories presented were weak and/or unreliable (although he deferred to
Dr. Shinnar on diagnostic issues specific to pediatric seizure disorders). Id. And he echoed Dr.
Shinnar’s emphasis on treater views, which in this case did not support vaccine causation (and to
the extent vaccination was even mentioned, did so in history sections of records in which G.J.B.’s
family recounted their version of his experiences). Id. at 7.

One point raised by Dr. Shinnar, but emphasized by Dr. MacGinnitie, was that most
accepted medical science associated inflammatory cytokines only with febrile seizures—but those

25
same cytokines had not been shown to be causal of afebrile seizures, let alone increased due to
vaccination in sufficient amounts to be harmful. First MacGinnitie Rep. at 4–6. Dr. Byers’s initial
report had only referenced only a few articles dealing with afebrile seizures, and they were either
specific to infections or did not offer any discussion of what the necessary cytokine levels would
be to produce seizure. See, e.g., Zhang at 1002, 1005; Lee at 162–63.

Indeed, one article (which Dr. Byers cited to but did not file—although Respondent offered
it later) specifically showed that cytokine levels were not increased in afebrile seizure patients, for
any of the cytokines Dr. Byers had proposed as potentially causal. First MacGinnitie Rep. at 4–5;
J. Choi et al., Increased Levels of HMGB1 and Pro-Inflammatory Cytokines in Children with
Febrile Seizures, 8 J. Neuroinflamm. 135, filed as Ex. C Tab 5 (ECF No. 33-6) (“Choi”). In Choi,
blood sera of 41 Korean children who had experienced febrile seizures were tested for cytokines,
against a comparably-sized group of children with a non-seizure febrile illness—as well as
different groups who had experienced afebrile seizures (or neither). Choi at 135. Choi’s authors
discovered that levels of the tested-for cytokines (including IL-1β and TNF-alpha) were routinely
higher in the febrile group, and not elevated in the afebrile controls. Choi at 139–40, 142 (noting
that “[t]he causative role of cytokine in epileptogenesis remains to be elucidated,” but stressing
that overall pro-inflammatory cytokine levels were higher in febrile seizure patients).

Next, Dr. MacGinnitie amplified Dr. Shinnar’s contention that increased levels of
cytokines in individuals suffering from seizures could be the result of seizure activity rather than
the cause. First MacGinnitie Rep. at 4. Cytokines, he pointed out, were understood to be “secreted
proteins that act as signaling molecules between cells,” and thus, they not only could proactively
impact seizure activity but could also be produced in the aftermath of seizure harm to the brain or
central nervous system. Id; Li at 250–52. For causation to be established herein, however, it needed
to be shown that vaccination was likely to instigate the increased production of these cytokines—
and (more importantly) at levels sufficiently high to be pathogenic.

Dr. MacGinnitie granted that animal studies existed that supported the contention that
inflammatory cytokines like IL-1β could lower the seizure threshold, but other evidence showing
heightened cytokine levels post-seizure did not establish a causation association (although he
acknowledged that measurement of cytokine levels in humans could only reliably be performed
post-seizure in the first place, making it very difficult to measure causation in any event).
Otherwise, higher levels of IL-1β (for example) found in “patients with intractable epilepsy and
afebrile status epilepticus” were more likely attributable to cytokines released due to seizure
activity—a “well-recognized phenomenon” in Dr. MacGinnitie’s view. First MacGinnitie Rep. at
5; Li at 249–50 (seizures enhance expression of IL-1β, although some studies revealed no
significant differences between IL-1β levels pre or post tonic-clonic seizures, and it otherwise is
difficult to use human blood serum testing to assess how the cytokine functions in human epilepsy
pathogenesis).

26
Dr. MacGinnitie also discussed the possibility of vaccines generally (and the MMR vaccine
specifically) to produce seizure. Of the many kinds of “immune challenge” individuals confront
on a daily basis, the risk posed by vaccines was far outweighed by wild infections. First
MacGinnitie Rep. at 6. Even though immune dysfunction and/or autoimmunity were potential
mediators for various illnesses, such processes would not simply appear in the wake of vaccination.
Overall, he deemed vaccination “a mild immune stimulus,” unlikely as a general matter to provoke
injury. Id. at 7.

The MMR vaccine in particular, Dr. MacGinnitie noted further, was only associated with
an elevated risk for febrile seizures (and Dr. Kinsbourne could only reference case reports to
support any other kind of association). First MacGinnitie Rep. at 6. N. Klein et al., Measles-
Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years, 129 Pediatrics 809, filed
as Ex. C Tab 9 (ECF No. 33-10) (“Klein”). Klein (which Dr. MacGinnitie deemed “a detailed
epidemiologic study”) considered Vaccine Safety Datalink evidence of seizures in a sample of
more than 60,000 children who had received the MMR vaccine or one containing its components,
and found no elevated risk of seizure within six weeks of vaccination. Klein at 812. At worst, there
was some increased risk of febrile seizure for infants 12-18 months old, but only after the first dose
(and that group did not apply to G.J.B., who was four years old at the time of the relevant
vaccinations). First MacGinnitie Rep. at 6; Klein at 813.

As an aside, Dr. MacGinnitie noted that the illustration contained in Dr. Byers’s first report,
which she had included to show how “cytokines can cause seizure independent of fever,” came
from Mazarati—not the article to which it referred. First MacGinnitie Rep. at 5–6. But Dr.
MacGinnitie offered the underlying article. See C. Dubé et al., Interleukin-1β Contributes to the
Generation of Experimental Febrile Seizures, 57 Ann. Neurol. 152 (2005), filed as Ex. C Tab 4
(ECF No. 33-5) (“Dubé”). In Dubé, researchers employed an animal model to evaluate what role
IL-1β likely played in causing or contributing to febrile seizures. Dubé at 152. In particular, Dubé’s
authors were interested in evaluating whether this cytokine might not only (because of its
proinflammatory and pyrogenic character) cause fevers that lead to seizures indirectly, but also
whether the cytokine could be shown or observed to play a more direct role in seizure pathogenesis.
It is known that in the context of a fever, brain microglia (central nervous system immune cells)18
release IL-1β, which can bind to certain receptors in portions of the brain and lead to “enhanced
neuronal excitability and decreased seizure threshold.” Id. Hence, there is some potential for the
cytokine to contribute or cause seizure activity that might occur outside, or independent to, the
context of a fever.

18
“Microglia” is defined as “the small, nonneural, interstitial cells of mesodermal origin that form part of the
supporting structure of the central nervous system. They are of various forms and may have slender branched
processes. They are migratory and act as phagocytes to waste products of nerve tissue. Microglia, Dorland’s
Medical Dictionary Online, https://www.dorlandsonline.com/dorland/definition?id=31308 (last visited May 22,
2023).

27
Dubé’s authors worked with mice specifically engineered to be deficient in the receptor
pertaining to IL-1β, and then used an experimental method to cause increased core and brain
temperatures in the mice comparable to what would be experienced in a fever, thereafter, inducing
seizures. Dubé at 152–53. They also directly administered IL-1β into some of the mice, at different
temporal stages of this process. They concluded that the cytokine was implicated “among the
mechanisms by which fever provokes seizure in the developing brain,” likely by contributing to
“the hyperexcitability and seizures” occurring after fever. Id. at 154–55. Importantly, however,
seizures could only be directly induced in the mice subjects by administration of “high doses” of
IL-1β; Dubé did not comment on whether vaccines (or infections) cause the body to produce the
cytokine in levels sufficient to provoke afebrile seizure in humans. Id. at 154.

Second Report

The final written report prepared by Dr. MacGinnitie (like his earlier report) responded to
Drs. Kinsbourne’s and Byers’s comments, with more emphasis on Dr. Byers’s criticisms. He began
by arguing that Dr. Byers had misconstrued several items of her own literature. Millichap, for
example, actually referenced an entirely different (but also not filed) article involving a large-scale
epidemiologic study which itself found no DTP (the whole-cell form of the DTaP vaccine no
longer administered) or MMR association with afebrile seizures—and therefore supported
Respondent’s position. Second MacGinnitie Rep. at 1–2; W. Barlow et al., The Risk of Seizures
After Receipt of Whole-Cell Pertussis or Measles, Mumps, and Rubella Vaccine, 345 N. Engl. J.
Med. 9:656 (2001), filed as Ex. F Tab 1 (ECF No. 44-2) (“Barlow”), at 660 (finding “significantly
elevated risks of febrile seizure” the day of DPT vaccine receipt, or 8-14 days after the MMR
vaccine, but no such risk for afebrile seizures “at any time after vaccination”) (emphasis added).
Barlow, a retrospective cohort study, looked at a total sample of over 675,000 children (seven
years old or less) enrolled in four health care maintenance organizations who had received the DPT
(again, the since-discontinued form of DTaP vaccine) and MMR vaccines—more than 477,000
doses. Barlow at 657, 660. It also characterized the observed enhanced risk of the MMR vaccine
to result in febrile seizures as only “transient.” Id. at 660. Another item, Eckerle, was a single-
patient case report involving the first dose of MMR vaccine, and did not, in Dr. MacGinnitie’s
opinion, constitute a reliable view on causation. Eckerle at 1094–95.

Lee and Ong, Dr. MacGinnitie noted, was similarly unhelpful to Petitioners’ claim. Second
MacGinnitie Rep. at 2. While this article focused on associations with “provoked” afebrile
seizures, the seizures G.J.B. had experienced could not be deemed provoked (especially since there
is no evidence he was at the time suffering from an infection). Rather, based on the taxonomy Lee
and Ong proposed (febrile, provoked, and true afebrile seizures), G.J.B.’s age (over four years old
at the time) made his experience more consistent with their description of afebrile seizures—
including the fact that (as the article reported) afebrile seizures were generally more likely to lead

28
to additional afebrile seizures, as was the case with G.J.B. Lee and Ong at 162–63. And Ha’s
comparisons of TNF-alpha cytokine levels in different patient groups did not also involve a control
group—nor had Ha’s authors collected blood samples soon enough after seizure activity to deem
the cytokines likely causal (as opposed to being a byproduct of the seizure activity). Ha at 160–
61.

Dr. MacGinnitie concluded by emphasizing the fact that epidemiologic evidence
underscored only a heightened risk of febrile seizures when a child was younger than 18 months
old, and primarily after the receipt of the first dose of vaccine. Second MacGinnitie Rep. at 2–3.
Evidence like Barlow, by contrast, reliably highlighted the lack of an association between vaccines
like the MMR and afebrile seizures. Barlow at 658.

III. Parties’ Arguments

A. Petitioners

Petitioners contend they have met all the prongs for establishing causation in fact under
Althen v. Sec’y of Health & Hum. Servs., 418 F.3d 1274, 1278 (Fed. Cir. 2005). First, they maintain
that they have offered reliable preponderant proof that the MMR and DTaP vaccines can trigger
afebrile seizures. Mot. at 10–13. Lee & Ong, for example, observed some afebrile post-infection
seizures as a possible middle category (between febrile seizures and seizure disorders due to some
preexisting genetic condition). Id. at 10–12; see also Chung & Wong at 592. Petitioners also
highlighted the case report and epidemiologic evidence in favor of their theory. Mot. at 14–18.
Some studies they offered had connected the MMR vaccine specifically with adverse events.
Weibel at 383–86 (noting association between the MMR vaccine and encephalopathy, and also
observing some instances where onset involved seizure (p. 386 Table 1). And the IOM itself only
determined that it could not “conclusively” associate the MMR vaccine with seizures—not that
the association lacked any evidentiary basis at all. Mot. at 19–21.

In addition, Petitioners attempted to distinguish Verbeek, arguing that its authors had not
persuasively rebutted the possibility of vaccines as triggering afebrile seizures in a large proportion
of studied children, and otherwise assumed without evidence that a genetic cause was always more
likely in such cases. Mot. at 21–23; Verbeek at 663–64. Verbeek also, in their reading, provided a
post-vaccination timeframe consistent with this case. Mot. at 21–22; Verbeek at 660. And its
determination was not inconsistent with the possibility of vaccines occasionally triggering seizures
in the absence of fever, as other items of literature allowed. Scheffer at 336. The term “trigger,”
Petitioners maintained, had to be distinguished from “cause”—with the former more consistent
with the legal exercise being conducted herein than the latter. Some individual susceptibility would
always be at issue when a vaccination sparked a seizure (even if the susceptibility did not rise to a
level of “genetic determinism”). Mot. at 25. And several other studies offered by Petitioner’s

29
experts were consistent with the MMR vaccine’s capacity to cause seizures. Id. at 26–28
(discussing Spiczak, Chung and Wong).

Petitioners further amplified their explanation of the role cytokines would play in triggering
post-vaccination afebrile seizures. Mot. at 28–32. Dr. Byers, they maintained, had offered a theory
supported by reliable articles (Li, Ha) that cytokines like IL-1β were well understood to play a role
in causing seizures leading to epilepsy, and that the pyrogenic (fever-causing) capacity of such
cytokines was independent from their seizure-provoking capability. Id. at 29–30. To the extent the
theory had limitations or omissions of support (in particular, whether vaccination upregulated these
cytokines sufficiently to trigger a seizure—let alone how—and/or whether the absence of the
effects of fever first had anything to do with the likelihood of seizure), Petitioners noted that the
preponderant standard applied to Vaccine Act claims did not require certainty, and that not enough
was known about the immune response in any event to require such evidence. Id. at 31. It was
enough, they maintained, that cytokines were involved in inflammatory responses and/or lowering
of the seizure threshold. Id. at 32.

With respect to the “did cause” prong, Petitioners argued that literature they had offered
supported the conclusion that under a “complex systems” conception of seizure disorders like
epilepsy, a first seizure episode was likely to provoke more similar instances later, even if the
inciting event was self-limiting—in effect, that “seizures beget seizures.” Mot. at 33–34; T. Sutula,
Mechanisms of Epilepsy Progression: Current Theories and Perspectives From Neuroplasticity in
Adulthood and Development, 70 Epilepsy Research 161 (2004), filed as Ex. 69 (ECF No. 42-9), at
164–65 (review article discussing brain harm occurring in wake of seizures, and interrelationship
between the same). The injury to the brain from the first event would be explanatory for the
subsequent course, and thus the vaccine(s) precipitating the first event were responsible for what
followed. There was also no reasonable alternative explanation for G.J.B.’s seizures, and no
evidence (“aside from some deficits in speech development,” which Petitioners offer no
explanation for) of any pre-onset issues. Mot. at 35–36. And G.J.B.’s five-day post-vaccination
first episode was consistent with vaccine cause, although Petitioners admitted there was no
cytokine testing that would directly confirm the theory working in real time, Id. at 36.

Petitioners also filed a reply—clocking in at 24 pages in length, and thus nearly as long as
Respondent’s opposition brief. In it, Petitioners took great umbrage at the criticisms lodged by
Respondent against Drs. Kinsbourne and Byers, but based on prior cases regarding their
qualifications or adequacy of expert opinions, maintaining that such attacks disregarded the
persuasiveness and validity of the opinions as offered herein. Reply at 2–5. Further, Petitioners
maintained that mere “plausibility” is the evidentiary standard applicable to the Althen prong one
showing, attempting to tease out support for that view from prior Federal Circuit decisions, and
distinguishing that evidentiary burden from the broader, clearly-preponderant standard applicable

30
to a claimant’s overall burden of proof. Id. at 5–9. Petitioners similarly defended the use of case
reports to support causation. Id. at 9–11.

Regarding specifics relevant to the opinions offered in the case, Petitioners reiterated their
contentions that they had met their burden. They attempted to rebut Dr. Shinnar’s contentions that
G.J.B.’s seizure disorder was consistent with what many children experience, disputing
specifically that Stratton II suggested afebrile seizures were less credibly associated with
vaccination than febrile, and maintaining that Dr. Shinnar had not even confronted Dr.
Kinsbourne’s theory. Reply at 12–18. Dr. MacGinnitie received comparable treatment. The
Petitioners acknowledged that he had directly addressed their theory, but contended that he had
mistakenly differentiated between afebrile and febrile seizures, without noting that the one
cytokine was common to both. Id. at 18–20. Petitioners also argued that alleged epidemiologic
studies that did not find a link between certain vaccines (MMR and DTaP) and afebrile seizures
were unreliable or unable to detect rare events, even if they involved large samples of
patients/subjects. Id. at 20–21.

B. Respondent

Respondent argues Petitioners have not met their burden of proof. Opp. at 22–27. First, he
maintains that it cannot be shown that any of the vaccines received by G.J.B. in July 2013 can
cause afebrile seizures. Opp. at 22–24. Respondent’s experts demonstrated not only that there was
a dearth of recent reliable literature supporting any broader association between certain vaccines
(particularly the MMR or DTaP) and afebrile seizures, but more specifically that Dr. Byers’s
proposed mechanism (pro-inflammatory cytokines upregulated in response to the vaccines causing
afebrile seizures) lacked substantiation. Id. at 22–23. Rather cytokines like IL-1β had only been
shown to be associated with febrile seizures (and even in that context, only for a younger cohort
that would not include G.J.B., since he was four when his first post-vaccination seizure
manifested). Choi at 139–40, 142. Otherwise, Respondent noted that reliable epidemiologic
studies, like Barlow, were unsupportive of a vaccine/afebrile seizure link, and Petitioner’s reliance
on case reports was misplaced since they were not probative of causation.

Second, Respondent contended that the “did cause” prong is not met. Opp. at 24–25. He
observed that none of G.J.B.’s treaters had directly opined his vaccines were associated with his
seizures; rather, records only referenced the prior fact of vaccination, but without proposing any
causal link. Id. at 24–25. Treaters had more often than not concluded they could not pinpoint a
cause for G.J.B.’s seizures, and Dr. Shinnar had noted that this (as well as the onset of the seizures
at age four) was common for epileptic patients. Id. G.J.B.’s family history also provided some
alternative factors that might better contextualize his seizure disorder, suggesting a genetic origin
as opposed to vaccination. Id. at 25.

31
Finally, Respondent denied that the timeframe for onset of seizures (which Respondent did
not squarely identify, although he did in his fact recitation note that G.J.B.’s first occurrence of
forgetting words had occurred within approximately five days from the date of vaccination) had
been shown to be medically acceptable, linking this contention to his earlier argument that
Petitioners did not show in the first place that the vaccines could cause afebrile seizures. Opp. at
26. Respondent also throughout this brief raised a number of objections to the qualifications and
competency of Drs. Kinsbourne and Byers (objections that as noted above prompted a fervent
reaction by Petitioners), maintaining that their lack of updated/recent treatment expertise, or
tendency to offer unreliable and garbled opinions that far exceed their demonstrated fields of
knowledge, had been raised as an issue in numerous prior special masters’ decisions. Id. at 13–17.

IV. Procedural History

Because this case was initiated in the summer of 2016, it is now nearly seven years old,
and was originally assigned to a different special master. The parties filed records and the expert
reports discussed above through mid-2019, and at that point some efforts to settle the case were
made, although they proved unsuccessful. The matter was reassigned to me in January 2021, and
I set it down for trial to be held in February 2022. ECF No. 64. However, in November 2021
Petitioners’ former counsel asked that the trial date be continued, since he intended to withdraw
from the matter. ECF No. 65. I took the case off the trial calendar, but opted instead to have the
parties brief entitlement and resolve the case via ruling on the record, given my concerns about the
case’s age (and attendant desire that it be resolved as expeditiously as possible). ECF No. 68. After
present counsel appeared in the matter for Petitioners, the parties filed their respective briefs, and
the matter is ripe for resolution.

V. Applicable Law

A. Petitioner’s Overall Burden in Vaccine Program Cases

To receive compensation in the Vaccine Program, a petitioner must prove either: (1) that
he suffered a “Table Injury”—i.e., an injury falling within the Vaccine Injury Table—
corresponding to one of the vaccinations in question within a statutorily prescribed period of time
or, in the alternative, (2) that his illnesses were actually caused by a vaccine (a “Non-Table
Injury”). See Sections 13(a)(1)(A), 11(c)(1), and 14(a), as amended by 42 C.F.R. § 100.3; §
11(c)(1)(C)(ii)(I); see also Moberly v. Sec’y of Health & Hum. Servs., 592 F.3d 1315, 1321 (Fed.
Cir. 2010); Capizzano v. Sec’y of Health & Hum. Servs., 440 F.3d 1317, 1320 (Fed. Cir. 2006).19

19
Decisions of special masters (some of which I reference in this ruling) constitute persuasive but not binding
authority. Hanlon v. Sec’y of Health & Hum. Servs., 40 Fed. Cl. 625, 630 (1998). By contrast, Federal Circuit rulings
concerning legal issues are binding on special masters. Guillory v. Sec’y of Health & Hum. Servs., 59 Fed. Cl. 121,
124 (2003), aff’d 104 F. Appx. 712 (Fed. Cir. 2004); see also Spooner v. Sec’y of Health & Hum. Servs., No. 13-159V,
2014 WL 504728, at *7 n.12 (Fed. Cl. Spec. Mstr. Jan. 16, 2014).

32
In this case, Petitioner cannot assert a Table claim based on the contention that the DTaP with IPV,
MMR, and Varicella vaccines can cause afebrile seizures.

For both Table and Non-Table claims, Vaccine Program petitioners bear a “preponderance
of the evidence” burden of proof. Section 13(1)(a). That is, a petitioner must offer evidence that
leads the “trier of fact to believe that the existence of a fact is more probable than its nonexistence
before [he] may find in favor of the party who has the burden to persuade the judge of the fact’s
existence.” Moberly, 592 F.3d at 1322 n.2; see also Snowbank Enter. v. United States, 6 Cl. Ct.
476, 486 (1984) (mere conjecture or speculation is insufficient under a preponderance standard).
Proof of medical certainty is not required. Bunting v. Sec’y of Health & Hum. Servs., 931 F.2d
867, 873 (Fed. Cir. 1991). In particular, a petitioner must demonstrate that the vaccine was “not
only [the] but-for cause of the injury but also a substantial factor in bringing about the injury.”
Moberly, 592 F.3d at 1321 (quoting Shyface v. Sec’y of Health & Hum. Servs., 165 F.3d 1344,
1352–53 (Fed. Cir. 1999)); Pafford v. Sec’y of Health & Hum. Servs., 451 F.3d 1352, 1355 (Fed.
Cir. 2006). A petitioner may not receive a Vaccine Program award based solely on his assertions;
rather, the petition must be supported by either medical records or by the opinion of a competent
physician. Section 13(a)(1).

In attempting to establish entitlement to a Vaccine Program award of compensation for a
Non-Table claim, a petitioner must satisfy all three of the elements established by the Federal
Circuit in Althen, 418 F.3d at 1278: “(1) a medical theory causally connecting the vaccination and
the injury; (2) a logical sequence of cause and effect showing that the vaccination was the reason
for the injury; and (3) a showing of proximate temporal relationship between vaccination and
injury.”

Each of the Althen prongs requires a different showing. Under Althen prong one, petitioners
must provide a “reputable medical theory,” demonstrating that the vaccine received can cause the
type of injury alleged. Pafford, 451 F.3d at 1355–56 (citations omitted). To satisfy this prong, a
petitioner’s theory must be based on a “sound and reliable medical or scientific explanation.”
Knudsen v. Sec’y of Health & Hum. Servs., 35 F.3d 543, 548 (Fed. Cir. 1994). Such a theory must
only be “legally probable, not medically or scientifically certain.” Id. at 549.

Petitioners may satisfy the first Althen prong without resort to medical literature,
epidemiological studies, demonstration of a specific mechanism, or a generally accepted medical
theory. Andreu v. Sec’y of Health & Hum. Servs., 569 F.3d 1367, 1378–79 (Fed. Cir. 2009) (citing
Capizzano, 440 F.3d at 1325–26). Special masters, despite their expertise, are not empowered by
statute to conclusively resolve what are essentially thorny scientific and medical questions, and
thus scientific evidence offered to establish Althen prong one is viewed “not through the lens of
the laboratorian, but instead from the vantage point of the Vaccine Act’s preponderant evidence
standard.” Id. at 1380. Accordingly, special masters must take care not to increase the burden

33
placed on petitioners in offering a scientific theory linking vaccine to injury. Contreras, 121 Fed.
Cl. at 245 (“[p]lausibility . . . in many cases may be enough to satisfy Althen prong one” (emphasis
in original)).

In discussing the evidentiary standard applicable to the first Althen prong, the Federal
Circuit has consistently rejected the contention that it can be satisfied merely by establishing the
proposed causal theory’s scientific or medical plausibility. See Boatmon v. Sec’y of Health & Hum.
Servs., 941 F.3d 1351, 1359 (Fed. Cir. 2019); see also LaLonde v. Sec’y of Health & Hum. Servs.,
746 F.3d 1334, 1339 (Fed. Cir. 2014) (“[h]owever, in the past we have made clear that simply
identifying a ‘plausible’ theory of causation is insufficient for a petitioner to meet her burden of
proof.” (citing Moberly, 592 F.3d at 1322)); see also Howard v. Sec'y of Health & Hum. Servs.,
No. 16-1592V, slip op., at *6 (Fed. Cl. Feb. 27, 2023) (“[t]he standard has been preponderance for
nearly four decades”). Petitioners consistently have the ultimate burden of establishing their
overall Vaccine Act claim with preponderant evidence. W.C. v. Sec’y of Health & Hum. Servs.,
704 F.3d 1352, 1356 (Fed. Cir. 2013) (citations omitted); Tarsell v. United States, 133 Fed. Cl.
782, 793 (2017) (noting that Moberly “addresses the petitioner’s overall burden of proving
causation-in-fact under the Vaccine Act” by a preponderance standard).

The second Althen prong requires proof of a logical sequence of cause and effect, usually
supported by facts derived from a petitioner’s medical records. Althen, 418 F.3d at 1278; Andreu,
569 F.3d at 1375–77; Capizzano, 440 F.3d at 1326; Grant v. Sec’y of Health & Hum. Servs., 956
F.2d 1144, 1148 (Fed. Cir. 1992). In establishing that a vaccine “did cause” injury, the opinions
and views of the injured party’s treating physicians are entitled to some weight. Andreu, 569 F.3d
at 1367; Capizzano, 440 F.3d at 1326 (“medical records and medical opinion testimony are favored
in vaccine cases, as treating physicians are likely to be in the best position to determine whether a
‘logical sequence of cause and effect show[s] that the vaccination was the reason for the injury’”)
(quoting Althen, 418 F.3d at 1280). Medical records are generally viewed as particularly
trustworthy evidence, since they are created contemporaneously with the treatment of the patient.
Cucuras v. Sec’y of Health & Hum. Servs., 993 F.2d 1525, 1528 (Fed. Cir. 1993).

Medical records and statements of a treating physician, however, do not per se bind the
special master to adopt the conclusions of such an individual, even if they must be considered and
carefully evaluated. Section 13(b)(1) (providing that “[a]ny such diagnosis, conclusion, judgment,
test result, report, or summary shall not be binding on the special master or court”); Snyder v. Sec’y
of Health & Hum. Servs., 88 Fed. Cl. 706, 746 n.67 (2009) (“there is nothing . . . that mandates
that the testimony of a treating physician is sacrosanct—that it must be accepted in its entirety and
cannot be rebutted”). As with expert testimony offered to establish a theory of causation, the
opinions or diagnoses of treating physicians are only as trustworthy as the reasonableness of their
suppositions or bases. The views of treating physicians should be weighed against other, contrary
evidence also present in the record—including conflicting opinions among such individuals.

34
Hibbard v. Sec’y of Health & Hum. Servs., 100 Fed. Cl. 742, 749 (2011) (not arbitrary or capricious
for special master to weigh competing treating physicians’ conclusions against each other), aff’d,
698 F.3d 1355 (Fed. Cir. 2012); Veryzer v. Sec’y of Dept. of Health & Hum. Servs., No. 06-522V,
2011 WL 1935813, at *17 (Fed. Cl. Spec. Mstr. Apr. 29, 2011), mot. for review denied, 100 Fed.
Cl. 344, 356 (2011), aff’d without opinion, 475 F. Appx. 765 (Fed. Cir. 2012).

The third Althen prong requires establishing a “proximate temporal relationship” between
the vaccination and the injury alleged. Althen, 418 F.3d at 1281. That term has been equated to the
phrase “medically-acceptable temporal relationship.” Id. A petitioner must offer “preponderant
proof that the onset of symptoms occurred within a timeframe which, given the medical
understanding of the disorder’s etiology, it is medically acceptable to infer causation.” de Bazan
v. Sec’y of Health & Hum. Servs., 539 F.3d 1347, 1352 (Fed. Cir. 2008). The explanation for what
is a medically acceptable timeframe must align with the theory of how the relevant vaccine can
cause an injury (Althen prong one’s requirement). Id. at 1352; Shapiro v. Sec’y of Health & Hum.
Servs., 101 Fed. Cl. 532, 542 (2011), recons. denied after remand, 105 Fed. Cl. 353 (2012), aff’d
mem., 503 F. Appx. 952 (Fed. Cir. 2013); Koehn v. Sec’y of Health & Hum. Servs., No. 11-355V,
2013 WL 3214877 (Fed. Cl. Spec. Mstr. May 30, 2013), mot. for rev. denied (Fed. Cl. Dec. 3,
2013), aff’d, 773 F.3d 1239 (Fed. Cir. 2014).

B. Legal Standards Governing Factual Determinations

The process for making determinations in Vaccine Program cases regarding factual issues
begins with consideration of the medical records. Section 11(c)(2). The special master is required
to consider “all [] relevant medical and scientific evidence contained in the record,” including “any
diagnosis, conclusion, medical judgment, or autopsy or coroner’s report which is contained in the
record regarding the nature, causation, and aggravation of the petitioner’s illness, disability, injury,
condition, or death,” as well as the “results of any diagnostic or evaluative test which are contained
in the record and the summaries and conclusions.” Section 13(b)(1)(A). The special master is then
required to weigh the evidence presented, including contemporaneous medical records and
testimony. See Burns v. Sec’y of Health & Hum. Servs., 3 F.3d 415, 417 (Fed. Cir. 1993) (it is
within the special master’s discretion to determine whether to afford greater weight to
contemporaneous medical records than to other evidence, such as oral testimony surrounding the
events in question that was given at a later date, provided that such determination is evidenced by
a rational determination).

Medical records that are created contemporaneously with the events they describe are
presumed to be accurate and “complete” (i.e., presenting all relevant information on a patient’s
health problems). Cucuras, 993 F.2d at 1528; Doe/70 v. Sec’y of Health & Hum. Servs., 95 Fed.
Cl. 598, 608 (2010) (“[g]iven the inconsistencies between petitioner’s testimony and his
contemporaneous medical records, the special master’s decision to rely on petitioner’s medical

35
records was rational and consistent with applicable law”), aff’d sub nom. Rickett v. Sec’y of Health
& Hum. Servs., 468 F. Appx. 952 (Fed. Cir. 2011) (non-precedential opinion). This presumption
is based on the linked propositions that (i) sick people visit medical professionals; (ii) sick people
honestly report their health problems to those professionals; and (iii) medical professionals record
what they are told or observe when examining their patients in as accurate a manner as possible,
so that they are aware of enough relevant facts to make appropriate treatment decisions. Sanchez
v. Sec’y of Health & Hum. Servs., No. 11-685V, 2013 WL 1880825, at *2 (Fed. Cl. Spec. Mstr.
Apr. 10, 2013); Cucuras v. Sec’y of Health & Hum. Servs., 26 Cl. Ct. 537, 543 (1992), aff’d, 993
F.2d at 1525 (Fed. Cir. 1993) (“[i]t strains reason to conclude that petitioners would fail to
accurately report the onset of their daughter’s symptoms”).

Accordingly, if the medical records are clear, consistent, and complete, then they should
be afforded substantial weight. Lowrie, 2005 WL 6117475, at *20. Indeed, contemporaneous
medical records are generally found to be deserving of greater evidentiary weight than oral
testimony—especially where such testimony conflicts with the record evidence. Cucuras, 993 F.2d
at 1528; see also Murphy, 23 Cl. Ct. at 733 (citing United States v. United States Gypsum Co., 333
U.S. 364, 396 (1947) (“[i]t has generally been held that oral testimony which is in conflict with
contemporaneous documents is entitled to little evidentiary weight.”)).

There are, however, situations in which compelling oral testimony may be more persuasive
than written records, such as where records are deemed to be incomplete or inaccurate. Campbell
v. Sec’y of Health & Hum. Servs., 69 Fed. Cl. 775, 779 (2006) (“like any norm based upon common
sense and experience, this rule should not be treated as an absolute and must yield where the factual
predicates for its application are weak or lacking”); Lowrie, 2005 WL 6117475, at *19 (“’[w]ritten
records which are, themselves, inconsistent, should be accorded less deference than those which
are internally consistent’”) (quoting Murphy, 23 Cl. Ct. at 733)). Ultimately, a determination
regarding a witness’s credibility is needed when determining the weight that such testimony should
be afforded. Andreu, 569 F.3d at 1379; Bradley v. Sec’y of Health & Hum. Servs., 991 F.2d 1570,
1575 (Fed. Cir. 1993).

When witness testimony is offered to overcome the presumption of accuracy afforded to
contemporaneous medical records, such testimony must be “consistent, clear, cogent, and
compelling.” Sanchez, 2013 WL 1880825, at *3 (citing Blutstein v. Sec’y of Health & Hum. Servs.,
No. 90-2808V, 1998 WL 408611, at *5 (Fed. Cl. Spec. Mstr. June 30, 1998)). In determining the
accuracy and completeness of medical records, the Court of Federal Claims has listed four possible
explanations for inconsistencies between contemporaneously created medical records and later
testimony: (1) a person’s failure to recount to the medical professional everything that happened
during the relevant time period; (2) the medical professional’s failure to document everything
reported to her or him; (3) a person’s faulty recollection of the events when presenting testimony;
or (4) a person’s purposeful recounting of symptoms that did not exist. Lalonde v. Sec’y of Health

36
& Hum. Servs., 110 Fed. Cl. 184, 203-04 (2013), aff’d, 746 F.3d 1334 (Fed. Cir. 2014). In making
a determination regarding whether to afford greater weight to contemporaneous medical records
or other evidence, such as testimony at hearing, there must be evidence that this decision was the
result of a rational determination. Burns, 3 F.3d at 417.

C. Analysis of Expert Testimony

Establishing a sound and reliable medical theory often requires a petitioner to present
expert testimony in support of his claim. Lampe v. Sec’y of Health & Hum. Servs., 219 F.3d 1357,
1361 (Fed. Cir. 2000). Vaccine Program expert testimony is usually evaluated according to the
factors for analyzing scientific reliability set forth in Daubert v. Merrell Dow Pharmaceuticals,
Inc., 509 U.S. 579, 594–96 (1993). See Cedillo v. Sec’y of Health & Hum. Servs., 617 F.3d 1328,
1339 (Fed. Cir. 2010) (citing Terran v. Sec’y of Health & Hum. Servs., 195 F.3d 1302, 1316 (Fed.
Cir. 1999)). “The Daubert factors for analyzing the reliability of testimony are: (1) whether a
theory or technique can be (and has been) tested; (2) whether the theory or technique has been
subjected to peer review and publication; (3) whether there is a known or potential rate of error
and whether there are standards for controlling the error; and (4) whether the theory or technique
enjoys general acceptance within a relevant scientific community.” Terran, 195 F.3d at 1316 n.2
(citing Daubert, 509 U.S. at 592–95).

The Daubert factors play a slightly different role in Vaccine Program cases than they do
when applied in other federal judicial fora (such as the district courts). Daubert factors are usually
employed by judges (in the performance of their evidentiary gatekeeper roles) to exclude evidence
that is unreliable and/or could confuse a jury. In Vaccine Program cases, by contrast, these factors
are used in the weighing of the reliability of scientific evidence proffered. Davis v. Sec’y of Health
& Hum. Servs., 94 Fed. Cl. 53, 66–67 (2010) (“uniquely in this Circuit, the Daubert factors have
been employed also as an acceptable evidentiary-gauging tool with respect to persuasiveness of
expert testimony already admitted”). The flexible use of the Daubert factors to evaluate the
persuasiveness and reliability of expert testimony has routinely been upheld. See e.g., Snyder, 88
Fed. Cl. at 742–45. In this matter (as in numerous other Vaccine Program cases), Daubert has not
been employed at the threshold, to determine what evidence should be admitted, but instead to
determine whether expert testimony offered is reliable and/or persuasive.

Respondent frequently offers one or more experts of his own in order to rebut a petitioner’s
case. Where both sides offer expert testimony, a special master’s decision may be “based on the
credibility of the experts and the relative persuasiveness of their competing theories.”
Broekelschen v. Sec’y of Health & Hum. Servs., 618 F.3d 1339,1347 (Fed. Cir. 2010) (citing
Lampe, 219 F.3d at 1362). However, nothing requires the acceptance of an expert’s conclusion
“connected to existing data only by the ipse dixit of the expert,” especially if “there is simply too
great an analytical gap between the data and the opinion proffered.” Snyder, 88 Fed. Cl. at 743

37
(quoting Gen. Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997)); see also Isaac v. Sec’y of Health &
Hum. Servs., No. 08-601V, 2012 WL 3609993, at *17 (Fed. Cl. Spec. Mstr. July 30, 2012), mot.
for rev. denied, 108 Fed. Cl. 743 (2013), aff’d, 540 F. Appx. 999 (Fed. Cir. 2013) (citing Cedillo,
617 F.3d at 1339). Weighing the relative persuasiveness of competing expert testimony, based on
a particular expert’s credibility, is part of the overall reliability analysis to which special masters
must subject expert testimony in Vaccine Program cases. Moberly, 592 F.3d at 1325–26
(“[a]ssessments as to the reliability of expert testimony often turn on credibility determinations”);
see also Porter v. Sec’y of Health & Hum. Servs., 663 F.3d 1242, 1250 (Fed. Cir. 2011) (“this
court has unambiguously explained that special masters are expected to consider the credibility of
expert witnesses in evaluating petitions for compensation under the Vaccine Act”).

Expert opinions based on unsupported facts may be given relatively little weight. See
Dobrydnev v. Sec’y of Health & Hum. Servs., 556 F. Appx. 976, 992–93 (Fed. Cir. 2014) (“[a]
doctor’s conclusion is only as good as the facts upon which it is based”) (citing Brooke Group Ltd.
v. Brown & Williamson Tobacco Corp., 509 U.S. 209, 242 (1993) (“[w]hen an expert assumes
facts that are not supported by a preponderance of the evidence, a finder of fact may properly reject
the expert’s opinion”)). Expert opinions that fail to address or are at odds with contemporaneous
medical records may therefore be less persuasive than those which correspond to such records. See
Gerami v. Sec’y of Health & Hum. Servs., No. 12-442V, 2013 WL 5998109, at *4 (Fed. Cl. Spec.
Mstr. Oct. 11, 2013), aff’d, 127 Fed. Cl. 299 (2014).

D. Consideration of Medical Literature

Both parties filed medical and scientific literature in this case, but not every filed item
factors into the outcome of this decision. While I have reviewed all the medical literature submitted
in this case, I discuss only those articles that are most relevant to my determination and/or are
central to Petitioner’s case—just as I have not exhaustively discussed every individual medical
record filed. Moriarty v. Sec’y of Health & Hum. Servs., 844 F.3d 1322, 1328 (Fed. Cir. 2016)
(“[w]e generally presume that a special master considered the relevant record evidence even
though he does not explicitly reference such evidence in his decision”) (citation omitted); see also
Paterek v. Sec’y of Health & Hum. Servs., 527 F. Appx. 875, 884 (Fed. Cir. 2013) (“[f]inding
certain information not relevant does not lead to—and likely undermines—the conclusion that it
was not considered”).

E. Determining Matter on Record Rather Than at Hearing

I have determined to resolve this case based on written submissions and evidentiary filings,
including the numerous expert reports that have been submitted, rather than hold a trial, and the
parties have not formally objected to this means of adjudication. My determination is consistent
with the Vaccine Act and Rules, which not only contemplate but encourage special masters to

38
decide petitions (or components of a claim) on the papers where (in the exercise of their discretion)
they conclude that such a means of adjudication will properly and fairly resolve the case. Section
12(d)(2)(D); Vaccine Rule 8(d). The Federal Circuit has affirmed this practice. Kreizenbeck v.
Sec’y of Health & Hum. Servs., 945 F.3d 1362, 1365–66 (Fed. Cir. 2020). It simply is not the case
that every Vaccine Act claim need be resolved by hearing—even where the

[Text truncated at 120,000 characters. The full text is on the page linked above.]

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/cases/10736786. Public record. Not legal advice.